medroxyprogesterone acetate profile

ID Source	ID
PubMed CID	6279
CHEMBL ID	717
CHEBI ID	6716
SCHEMBL ID	4276
MeSH ID	M0026185

Synonym
MLS002207115
smr000653524
MLS001148217 ,
AB00384270-14
17-acetoxy-6.alpha.-methylprogesterone
(6.alpha.-pregn-4-ene-3, 17-(acetyloxy)-6-methyl-
oragest
prodasone
MAP ,
nsc-21171
veramix
metigestrona
6.alpha.-methyl-17-acetoxyprogesterone
lutopolar
depcorlutin
6.alpha.-methyl-17.alpha.-acetoxyprogesterone
dp150
pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate
progestalfa
nsc26386
provera
6.alpha.-pregn-4-ene-3, 17-(acetyloxy)-6-methyl-
farlutin
17.alpha.-acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione
17.alpha.-hydroxy-6.alpha.-methylprogesterone acetate
sirprogen
nsc-26386
nadigest
17.alpha.-hydroxy-6-.alpha.-methylprogesterone acetate
progevera
depot-medroxyprogesterone acetate
u 8839
gestapuran
proverone
depomedroxyprogesterone acetate
repromix
promone-e
6.alpha.-methyl-17.alpha.-hydroxyprogesterone acetate
17.alpha.-hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate
supprestral
6.alpha.-methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate
perlutex
pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)-
nidaxin
nsc21171
deporone
onco-provera
17.alpha.-acetoxy-6.alpha.-methylprogesterone
6.alpha.-methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione
depo-provera
depo-promone
medroxyprogesterone 17 acetate
cbp-1011
CHEBI:6716 ,
medroxyprogesteroneacetate
NCGC00022037-03
mpa-noury
veraplex
ccris 371
sumiferm
medrosterona
clinovir
17alpha-hydroxy-6-alpha-methylprogesterone acetate
(6-alpha)-pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-
depo-clinovir
dugen
meprate
nsc 21171
6alpha-methyl-17alpha-acetoxypregn-4-ene-3,20-dione
6-alpha-methyl-17-alpha-acetoxypregn-4-ene-3,20-dione
mpa gym
mpa-beta
map (steroid)
indivina
medroxyprogesterone acetate [jan]
medroxyprogesterone acetate [progestins]
brn 2066112
aragest
depo-ralovera
17-alpha-acetoxy-6-alpha-methylpregn-4-ene-3,20-dione
mpa hexal
cycrin
perlutex leo
6alpha-pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-
ralovera
progesterone, 17-hydroxy-6alpha-methyl-, acetate
hysron
depo-map
cykrina
amen
ai3-60127
clinofem
depo-subq provera 104
17-alpha-hydroxy-6-alpha-methylprogesterone acetate
depocon
einecs 200-757-9
mepastat
6alpha-methyl-17alpha-acetoxyprogesterone
depo-medroxyprogesterone acetate
6alpha-methyl-17-acetoxyprogesterone
6-alpha-methyl-4-pregnene-3,20-dion-17-alpha-ol acetate
depo-progevera
provera dosepak
depo-prodasone
17-hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate
progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate
depo-progestin
17-acetoxy-6-alpha-methylprogesterone
suprestral
repromap
17alpha-acetoxy-6-alpha-methylpregn-4-ene-3,20-dione
med-pro
pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-
depot medroxyprogesterone acetate
6-alpha-methyl-17-acetoxy progesterone
aragest 5
17-alpha-hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate
17alpha-hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate
pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate
17alpha-acetoxy-6alpha-methylprogesterone
(6-alpha)-17-(acetyloxy)-6-methylpreg-4-ene-3,20-dione
medroxyprogesterone acetate ,
6-alpha-methyl-17-alpha-hydroxyprogesterone acetate
C08150
6-alpha-methyl-17-alpha-acetoxyprogesterone
medroxyprogesterone 17-acetate, >=97% (hplc)
6alpha-methyl-17alpha-hydroxyprogesterone acetate
(6alpha)-17-(acetyloxy)-6-methylpreg-4-ene-3,20-dione
medroxyprogesterone 17-acetate
DB00603
17-acetoxy-6alpha-methylprogesterone
17alpha-hydroxy-6alpha-methylprogesterone acetate
medroxyacetate progesterone
6alpha-methyl-17-acetoxy progesterone
methylacetoxyprogesterone
6alpha-methyl-4-pregnene-3,20-dion-17alpha-ol acetate
depo-provera (tn)
medroxyprogesterone acetate (jp17/usp)
provera (tn)
depo-subq provera 104 (tn)
D00951
NCGC00094713-01
NCGC00022037-04
MLS000069442 ,
smr000059125
(6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate
AC-2174
medroxyprogesteroni acetas
medroxiprogesterone acetate
tv-46046
CHEMBL717
bdbm50067678
cpd000653524
NCGC00022037-05
HMS3259O14
NCGC00257695-01
tox21_200141
dtxcid905527
tox21_111319
cas-71-58-9
dtxsid0025527 ,
HMS2235E05
HMS2233O07
unii-c2qi4ioi2g
medroxyprogesterone acetate [usp:jan]
depo-provera contraceptive
4-08-00-02212 (beilstein handbook reference)
c2qi4ioi2g ,
depo-subq provera
medroxyprogesterone acetate [mart.]
pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6.alpha.)-
medroxyprogesterone acetate [iarc]
medroxyprogesterone acetate [usp monograph]
lunelle component medroxyprogesterone acetate
medroxyprogesterone acetate component of prempro
medroxyprogesterone acetate [orange book]
medroxyprogesterone acetate component of lunelle
medroxyprogesterone 17-acetate [mi]
prempro component medroxyprogesterone acetate
medroxyprogesterone acetate component of premphase
medroxyprogesterone acetate [who-ip]
premphase component medroxyprogesterone acetate
medroxyprogesterone acetate [vandf]
medroxyprogesterone acetate [usp-rs]
medroxyprogesterone acetate [ep monograph]
megestrol acetate impurity a [ep impurity]
medroxyprogesterone acetate [who-dd]
medroxyprogesteroni acetas [who-ip latin]
AKOS015894870
S2567
HY-B0469
NC00574
SCHEMBL4276
NCGC00263480-01
tox21_111319_1
PSGAAPLEWMOORI-PEINSRQWSA-N
(6?)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate
pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-
AB00384270_15
OPERA_ID_1110
medroxyprogesterone-17-acetate
medroxyprogesterone (acetate)
(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl acetate
medroxyprogesterone 17-acetate, vetranal(tm), analytical standard
medroxyprogesterone acetate, united states pharmacopeia (usp) reference standard
medroxyprogesterone acetate, pharmaceutical secondary standard; certified reference material
medroxyprogesterone acetate for peak identification, european pharmacopoeia (ep) reference standard
medroxyprogesterone acetate, for performance test, european pharmacopoeia (ep) reference standard
medroxyprogesterone acetate for system suitability, european pharmacopoeia (ep) reference standard
medroxyprogesterone acetate, european pharmacopoeia (ep) reference standard
MRF-0000023
NCGC00022037-07
Q2823834
medroxyprogesterone-17-acetate 100 microg/ml in acetonitrile
AS-13981
HMS3884B10
medroxyprogesterone-acetate
CCG-264965
C76275
HY-B0469R
medroxyprogesterone acetate (standard)
CS-0694837
EN300-7480751
(1r,3as,3br,5s,9ar,9bs,11as)-1-acetyl-5,9a,11a-trimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl acetate

Excerpt	Reference	Relevance
"Medroxyprogesterone acetate (MPA) is a progestin widely used in humans as hormone replacement therapy and at other indications. "	( Medroxyprogesterone acetate positively modulates specific GABA Bäckström, T; Das, R; Druzin, M; Haage, D; Johansson, M; Johansson, S; Ragagnin, G; Sjöstedt, J, 2022)	3.61
"Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical use for various hormonal conditions in women since the 1960s. "	( Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. Ebrahimie, E; Hanson, AR; Hickey, TE; Moore, NL; Tilley, WD, 2020)	2.26
"Medroxyprogesterone acetate (MPA) is a widely used synthetic progestin in contraception pills and hormone replacement therapy. "	( Medroxyprogesterone acetate affects eye growth and the transcription of associated genes in zebrafish. Chen, HX; Hou, LP; Huang, GY; Huang, MZ; Jiang, YX; Ma, DD; Shi, WJ; Xie, L; Ying, GG, 2020)	3.44
"Medroxyprogesterone acetate (MPA) is a frequently used hormonal contraceptive that has been shown to significantly increase HIV-1 susceptibility by approximately 40 %. "	( Transcriptional response of vaginal epithelial cells to medroxyprogesterone acetate treatment results in decreased barrier integrity. Bagri, P; Dupont, H; Kaushic, C; Lam, J; Nazli, A; Verschoor, CP; Woods, MW; Zahoor, MA, 2021)	2.31
"As medroxyprogesterone acetate is a cytochrome P450 (CYP3A4) substrate, drug-drug interactions (DDIs) with antiretroviral or antituberculosis treatment may lead to subtherapeutic medroxyprogesterone acetate concentrations (< 0.1 ng/mL), resulting in contraception failure, when depot medroxyprogesterone is dosed at 12-week intervals."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	1.39
"Medroxyprogesterone acetate (MPA) is a potent progestin with an anti-inflammatory property, but its effect on macrophage differentiation is unknown."	( Medroxyprogesterone acetate drives M2 macrophage differentiation toward a phenotype of decidual macrophage. Huang, JY; Kuo, PL; Su, MT; Tsai, YC; Tseng, JT; Wang, CY, 2017)	2.62
"Depo-medroxyprogesterone acetate (DMPA) is an injectable progestin contraceptive that provides a highly effective reduction of pelvic pain in women with endometriosis. "	( Differential expressions of estrogen and progesterone receptors in endometria and cyst walls of ovarian endometrioma from women with endometriosis and their responses to depo-medroxyprogesterone acetate treatment. Changklungmoa, N; Lertvikool, S; Poljaroen, J; Sobhon, P; Songkoomkrong, S; Sophonsritsuk, A; Sroyraya, M; Tingthanatikul, Y; Weerakiet, S; Wongkularb, A, 2018)	1.19
"Medroxyprogesterone acetate (MPA) is a widely used synthetic progestin and it has been frequently detected in aquatic environments. "	( Medroxyprogesterone acetate affects sex differentiation and spermatogenesis in zebrafish. Chen, HX; Hou, LP; Huang, GY; Jiang, YX; Liu, YS; Ma, DD; Shi, WJ; Xie, L; Ying, GG; Zhang, JN, 2019)	3.4
"Medroxyprogesterone acetate (MPA) is a widely used progestin in feminizing hormone therapy. "	( Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results From a Retrospective Study. Forcier, M; Jain, J; Kwan, D, 2019)	3.4
"Medroxyprogesterone acetate (MPA) is a synthetic progestin commonly administered to postmenopausal women for hormone replacement therapy and has been associated with increased risk of breast cancer. "	( Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced breast cancer model. Besch-Williford, CL; Cook, M; Hyder, SM; Mafuvadze, B; Xu, Z, 2013)	2.06
"Medroxyprogesterone acetate (MPA) is a synthetic progestin commonly used in hormone replacement therapy (HRT). "	( Differential regulation of endothelium behavior by progesterone and medroxyprogesterone acetate. Campelo, AE; Cutini, PH; Massheimer, VL, 2014)	2.08
"Medroxyprogesterone acetate (MPA) is an endocrine therapeutic drug."	( [Medroxyprogesterone Acetate as Part of Palliative Care for Terminal-Stage Breast Cancer Patients--A Report of Two Cases]. Amaya, F; Fukazawa, K; Harada, A; Hatano, T; Hosokawa, T; Kwon, C; Nakasone, A; Okada, M; Okamoto, A; Onishi, K; Taguchi, T; Taniguchi, A; Ueno, H; Yamashiro, A, 2016)	2.07
"Medroxyprogesterone acetate (MPA) is a synthetic, orally active derivative of the natural steroid hormone progesterone, widely used in oncology both in the endocrine treatment of hormone-related cancers and as supportive therapy in the cachexia syndrome."	( Medroxyprogesterone acetate in the management of cancer cachexia. Macciò, A; Madeddu, C; Mantovani, G; Panzone, F; Tanca, FM, 2009)	3.24
"Depo-medroxyprogesterone acetate (DMPA) is an injectable contraceptive that contains the same progestin as the menopausal hormone therapy regimen found to increase breast cancer risk among postmenopausal women in the Women's Health Initiative clinical trial. "	( Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Beaber, EF; Daling, JR; Li, CI; Malone, KE; Porter, PL; Tang, MT, 2012)	1.25
"Medroxyprogesterone acetate (MPA) is a drug commonly used in endocrine therapy for advanced breast cancer, although it is known to cause thrombosis as a serious side effect. "	( Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Chiba, K; Hosokawa, M; Kobayashi, K; Mimura, N; Nakamura, Y; Shimada, N, 2003)	2.12
"Depo-medroxyprogesterone acetate (DMPA) is an effective injectable contraceptive with worldwide availability. "	( Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Felix, JC; Jain, JK; Kuo, J; Lu, JJ; Nicosia, AF; Nucatola, DL, 2003)	1.06
"Medroxyprogesterone acetate is an acceptable, though less effective, alternative."	( Hormone treatment of the adult transsexual patient. Gooren, L, 2005)	1.05
"Medroxyprogesterone acetate (MPA) is a synthetic hormone widely used in the adjuvant treatment of advanced breast cancer, hormone replacement therapy and in oral contraceptives."	( Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Manninen, T; Pennanen, P; Purmonen, S; Ylikomi, T, 2008)	1.07
"Medroxyprogesterone acetate (MPA) is a drug commonly used in endocrine therapy for advanced or recurrent breast cancer and endometrial cancer. "	( Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Chiba, K; Fujii, H; Kobayashi, K; Mimura, N; Minami, H; Sasaki, Y; Shimada, N, 2000)	2
"Medroxyprogesterone acetate (MPA) is a synthetic alpha-hydroxyprogesterone analog that has been extensively employed in therapeutics for its Pg-like actions, but that also has some glucocorticoid and androgen activity."	( Effect of medroxyprogesterone acetate on thyrotropin secretion in adult and old female rats. Borges, PP; Curty, FH; Lisboa, PC; Moreira, RM; Moura, EG; Pazos-Moura, CC, 2000)	1.43
"Depo-medroxyprogesterone acetate (DMPA) is an increasingly popular contraceptive choice among Navajo women. "	( Depo-provera associated with weight gain in Navajo women. Espey, E; Ogburn, T; Qualls, C; Steinhart, J, 2000)	0.82
"Medroxyprogesterone acetate (MPA) is an anti-cancer drug for mammary carcinomas and an angiostatic steroid. "	( Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Ashino-Fuse, H; Iwaguchi, T; Oikawa, T; Shimamura, M; Takano, Y, 1989)	3.16
"Medroxyprogesterone acetate (Provera) is a drug that is commonly given to young women with cancer during chemotherapy and radiation to control heavy bleeding associated with anovulation. "	( The effect of medroxyprogesterone acetate (Provera) on ovarian radiosensitivity. Barr, R; Belbec, L; Jarrell, J; McMahon, A; O'Connell, G; YoungLai, EV, 1989)	2.08
"Medroxyprogesterone acetate (MPA) is a synthetic progestin, currently used in the adjuvant treatment of advanced breast cancer, which induces remission rates (30-40%) comparable to those obtained with other types of endocrine therapies. "	( Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Baker, D; Labrie, F; Poirier, D; Poulin, R, 1989)	1.95
"Medroxyprogesterone acetate (MPA) is a synthetic progestin that is reported to be effective in the treatment of paraphilic behavior, including paraphilic aggression, in men. "	( Pre-optic and hypothalamic neurons accumulate [3H]medroxyprogesterone acetate in male cynomolgus monkeys. Bonsall, RW; Michael, RP; Rees, HD, 1986)	1.97
"Medroxyprogesterone acetate is an effective hormonal agent in the treatment of metastatic breast cancer."	( Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Blumenschein, GR; Buzdar, AU; Fraschini, G; Frye, D; Halvorson, HC; Hortobagyi, GN; Hug, V; Pinnamaneni, K; Yap, HY, 1985)	1.5

Excerpt	Reference	Relevance
"Medroxyprogesterone acetate (MPA) which has a steroid structure, is widely used in oncology practice in the treatment of the cachexia of cancer and to reduce hematologic toxicity in patients receiving chemotherapy. "	( The in-vitro effects of medroxyprogesterone acetate on acidic pH induced apoptosis of periferal blood mononuclear cells. Aydin, F; Büyükcelik, A; Kavgaci, H; Ovali, E; Ozdemir, F; Sönmez, M; Ucar, F, 2004)	2.07
"Medroxyprogesterone acetate (MPA) has an inducing effect on the hepatic drug-metabolizing enzyme system in the rat. "	( Medroxyprogesterone acetate improvement of the hepatic drug-metabolizing enzyme system in rats after chemical liver injury. Kärki, NT; Saarni, HU; Sotaniemi, EA; Stengård, J, 1983)	3.15
"Medroxyprogesterone acetate has a physiological progesterone-like thermal effect. "	( Medroxyprogesterone increases basal temperature: a placebo-controlled crossover trial in postmenopausal women. Barr, SI; McKay, DW; Prior, JC; Vigna, YM, 1995)	1.73
"Medroxyprogesterone acetate (MPA) has been successfully used as an adjuvant to gonadotrophin in the PPOS protocol."	( New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Ai, A; Chang, HY; Gao, H; Kuang, Y; Liu, Y; Long, H; Lyu, Q; Quan, X; Yu, S; Zhu, J, 2018)	1.2
"Medroxyprogesterone acetate (MPA) (1) has been transformed by two filamentous fungi, including Absidia griseolla var. "	( The 11α-hydroxylation of medroxyprogesterone acetate by Absidia griseolla var. igachii and Acremonium chrysogenum. Ghasemi, S; Habibi, Z; Heidary, M, 2019)	2.26
"Medroxyprogesterone acetate (MPA) has widely been used in hormone replacement therapy (HRT), and is associated with an increased risk of breast cancer, possibly due to disruption of androgen receptor (AR) signaling. "	( Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Δ(4)-tibolone. Bianco-Miotto, T; Birrell, SN; Buchanan, G; Butler, LM; Giorgio, L; Harris, JM; Leach, DA; Lee, AM; Need, EF; Newman, MR; O'Loughlin, MA; Ochnik, AM; Swinstead, EE; Trotta, AP, 2014)	2.07
"Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases. "	( Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? Bhavnani, BR; Stanczyk, FZ, 2014)	2.3
"Medroxyprogesterone acetate (MPA) which has a steroid structure, is widely used in oncology practice in the treatment of the cachexia of cancer and to reduce hematologic toxicity in patients receiving chemotherapy. "	( The in-vitro effects of medroxyprogesterone acetate on acidic pH induced apoptosis of periferal blood mononuclear cells. Aydin, F; Büyükcelik, A; Kavgaci, H; Ovali, E; Ozdemir, F; Sönmez, M; Ucar, F, 2004)	2.07
"Medroxyprogesterone acetate has been used prophylactically in 35 patients with stages I and IIIA renal cell carcinoma who had undergone radical nephrectomy. "	( Postoperative prophylactic use of progesterone in renal cell carcinoma. Fukushima, S; Furuhata, A; Kondo, I; Satomi, Y; Takai, S, 1982)	1.71
"Medroxyprogesterone acetate (MPA) has an inducing effect on the hepatic drug-metabolizing enzyme system in the rat. "	( Medroxyprogesterone acetate improvement of the hepatic drug-metabolizing enzyme system in rats after chemical liver injury. Kärki, NT; Saarni, HU; Sotaniemi, EA; Stengård, J, 1983)	3.15
"Medroxyprogesterone acetate has a physiological progesterone-like thermal effect. "	( Medroxyprogesterone increases basal temperature: a placebo-controlled crossover trial in postmenopausal women. Barr, SI; McKay, DW; Prior, JC; Vigna, YM, 1995)	1.73
"Medroxyprogesterone acetate (MPA) has been administered to rats and dogs. "	( Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Dey, M; Enever, R; Latta, D; Smith, D; Weierstall, R, 1993)	2
"Medroxyprogesterone acetate (MPA) has been used as an endocrine therapeutic agent for patients with breast cancer."	( Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Kurebayashi, J; Otsuki, T; Sonoo, H; Yamamoto, S, 1999)	2.47
"Medroxyprogesterone acetate (MPA) has been used in high doses as hormone treatment for metastatic breast cancer. "	( Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Haltia, M; Jääskeläinen, J; Kärkkäinen, J; Laasonen, E; Troupp, H, 1986)	1.96

Excerpt	Reference	Relevance
"Medroxyprogesterone acetate (MPA) did not cause any alteration in the specific activities of these enzymes as well as levels of cholesterol and phospholipids."	( Modification of aflatoxin B1-induced changes in certain mitochondrial enzymes and lipids by medroxyprogesterone acetate. Majumdar, S; Malik, V; Nagpaul, JP; Singh, R; Vohra, R, )	1.07

Excerpt	Reference	Relevance
"Medroxyprogesterone acetate treatment for her dysfunctional uterine bleeding was unsuccessful."	( Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. Osswald, M; Repine, T, 2004)	1.04
"Medroxyprogesterone acetate treatment, in the presence of lipopolysaccharide, was unable to prevent the lipopolysaccharide-induced increase in Toll-like receptor 4 messenger RNA and protein in the uterus."	( Can medroxyprogesterone acetate alter Toll-like receptor expression in a mouse model of intrauterine inflammation? Elovitz, MA; Mrinalini, C, 2005)	1.61
"Medroxyprogesterone acetate treatment was more effective than 17-alpha hydroxyprogesterone caproate treatment in the prevention of preterm birth and resulted in live pups at term."	( The use of progestational agents for preterm birth: lessons from a mouse model. Elovitz, MA; Mrinalini, C, 2006)	1.06
"Medroxyprogesterone acetate-treated ewes given estradiol had more prolonged suppression of serum FSH concentrations (6-18 h) and a delay in the induced FSH peak (32.3+/-3.3 vs."	( Synchronization of follicular wave emergence in the seasonally anestrous ewe: the effects of estradiol with or without medroxyprogesterone acetate. Barrett, DM; Bartlewski, PM; Davies, KL; Duggavathi, R; Epp, T; Huchkowsky, SL; Rawlings, NC, 2008)	1.28
"Medroxyprogesterone acetate (MAP) in the treatment of advanced breast cancer has been regarded as a minor agent according to the previous reports when used at low doses (less than 500 mg/day). "	( Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. Endo, K; Iino, Y; Izuo, M, 1981)	2.06
"Oral medroxyprogesterone acetate treatment in two patients was associated with a striking decrease in both plasma testosterone concentration and height velocity."	( Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. Grumbach, MM; Kaplan, SL; Rosenthal, SM, 1983)	0.91
"Medroxyprogesterone acetate (MPA) treatment resulted in a time- and dose-dependent decrease in IGFBP 4 and 5 mRNA abundance and secretion of these proteins, while little if any effect was observed on IGFBP 2 expression."	( Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens. Coutts, A; Murphy, LC; Murphy, LJ, 1994)	1.01
"Medroxyprogesterone acetate treatment significantly reduced the tumor volume of Capan-2 and also caused delayed growth in two other cell lines, AsPC-1 and MiaPaCa-2."	( Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Kuramoto, M; Ogawa, M; Yamashita, J, 1995)	1.01
"Medroxyprogesterone acetate (MPA)-treatment suppresses serum gonadotropin and androgen concentrations in women with polycystic ovarian disease (PCOD). "	( Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Anttila, L; Erkkola, R; Irjala, K; Koskinen, P; Ruutiainen, K, 1994)	1.96
"E2 + medroxyprogesterone acetate-treated HESCs demonstrated a dramatic reduction in Sp3 expression after progestin treatment, and Northern blots demonstrated progestational increases in Sp1 and reduction in Sp3 mRNA expression compared with controls."	( Regulation of tissue factor gene expression in human endometrium by transcription factors Sp1 and Sp3. Demopoulos, R; Guller, S; Krikun, G; Lockwood, CJ; Mackman, N; Schatz, F, 2000)	0.76
"Medroxyprogesterone acetate (MPA) treatment has been shown to exert several beneficial effects in cancer patients. "	( Mass spectrometric and high-performance liquid chromatographic studies of medroxyprogesterone acetate metabolites in human plasma. Bauer, T; Häberlein, H; Plaum, T; Stalker, DJ; Sturm, G, 1991)	1.95
"Pretreatment with medroxyprogesterone acetate decreased the lipopolysaccharide-induced up-regulation of Toll-like receptor 2 and 4 messenger RNA in the cervix and placenta."	( Can medroxyprogesterone acetate alter Toll-like receptor expression in a mouse model of intrauterine inflammation? Elovitz, MA; Mrinalini, C, 2005)	1.21
"Treatment with medroxyprogesterone acetate resulted in disappearance of these cysts."	( Cystic ovaries in a pre-term newborn infant. Bergqvist, C; Esscher, T; Lindgren, PG; Lundkvist, K; Sedin, G, 1984)	0.61
"Treatment with medroxyprogesterone acetate (Depo-Provera) in one case and with leuprolide acetate (Lupron-Depot) in the other suppressed gonadotropin levels, and behavior improved markedly."	( Gonadotropin-associated psychosis in perimenstrual behavior disorder. Abrams, CA; Chasalow, FI; Constant, M, 1993)	0.63
"Treatment with medroxyprogesterone acetate resulted in an improved response to carbon dioxide, and assisted ventilation was no longer needed."	( Alveolar hypoventilation treated with medroxyprogesterone. Lagercrantz, H; Löfgren, O; Milerad, J, 1985)	0.61

Excerpt	Reference	Relevance
" Acceptance of this approach, however, appears to have preceded detailed evaluation of possible adverse side effects of progestins that could result in patient noncompliance."	( A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy. Carmichael, JA; Hahn, PM; Kirkham, C; Reid, RL; Van Vugt, DA, 1991)	0.5
"Orchiectomy is considered a safe and simple procedure, free from serious side effects, in the treatment of prostatic carcinoma."	( Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Charig, CR; Rundle, JS, 1989)	0.28
" Hematological changes in the peripheral blood were compared between concomitant MPA patients and those not receiving MPA to examine the effect of MPA in reducing the marrow depression which is the major side effect of CAP."	( [Effect of medroxyprogesterone acetate on side effects of CAP therapy in gynecological malignant tumors]. Okamura, S; Okazaki, T; Sugimoto, O; Ueki, M; Yanagawa, Y, 1989)	0.67
" and, especially, the presence of previous cardiovascular disease represented adverse factors in the development of cardiovascular toxicity."	( Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer tria de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S, 1986)	0.5
"Both tibolone and CEE/MPA were safe with respect to effects on the endometrium and both treatments induced changes in the plasma profiles of certain lipid and lipoprotein parameters."	( A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Arrighi, B; Benencia, HJ; Berg, G; Halperin, H; Mesch, V; Pilnik, S; Siseles, NO; Wikinski, RW, 1995)	0.29
" Very few of the women used condoms, although 38% knew how to practice safe sex."	( Use of hormonal contraceptives in an institutional setting: reasons for use, consent and safety in women with psychiatric and intellectual disabilities. Egan, TM; Fairley, NA; Siegert, RJ, 1993)	0.29
" No adverse side effects have been found if pregnancy does occur."	( Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. Nelson, AL, 1996)	0.53
" There were no significant adverse effects on long term growth and development in DMPA exposed children and no delays in return to fertility."	( Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg, A; Evans, M; Gbolade, B; Newton, J; Pollard, L; Szarewski, A; Thomas, C; Walling, M, 1999)	0.3
" The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives."	( Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lu Cromie, MA; Garceau, RJ; Kaunitz, AM, 1999)	0.52
" The Workshop members endorse injectable contraceptives as safe and effective and recommend that they be made available to all women."	( Injectable contraceptives: safe and effective. , 1982)	0.26
" The FDA public board of inquiry sought to resolve the following issues concerning Depo-Provera: in comparison with other contraceptive drugs, do the benefits outweigh the risks; do data from animal studies indicate a potential risk of breast or endometrial cancer in humans from Depo-Provera; can the human studies' data refute the risk of human cancer suggested by the animal data; are there labeling conditions and distribution controls that would permit marketing of Depo-Provera as a safe and effective drug on a limited basis; would marketing approval of Depo-Provera as a contraceptive increase the use of the drug under conditions not stipulated in the approval; does use of Depo-Provera increase the risk of teratogenic effects to a greater extent than other systemic contraceptives in the event of a failure; and is estrogen therapy likely to be prescribed for a significant number of patients using Depo-Provera."	( FDA board investigates Depo-Provera safety. , 1983)	0.27
" Some medical professionals maintain Depo is both safe and effective and could curb rapid population growth worldwide."	( Injectable contraceptives: how safe are they? , 1979)	0.26
" Considering the risk benefit ratio, the advantages of sterilization far outweigh any adverse effects and contribute significantly to the improvement and promotion of family health."	( Weighing risks against benefits in contraceptive safety. Akhter, HH, 1983)	0.27
" This side effect was mainly noted in the first few months of use."	( Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa. Beksinska, ME; Rees, HV, 2001)	0.31
" DMPA (DEPO-PROVERA-150) is the very effective and safe method of family planning."	( [Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland]. Lech, MM, 2003)	0.77
" We investigated the role of synthetic progestins in initiating the adverse events associated with estrogen therapy."	( Progestins initiate adverse events of menopausal estrogen therapy. Clark, L; Garces, A; Rhodin, J; Thomas, T, 2003)	0.32
" No adverse drug reactions specific to E2V/MPA triphasic were observed."	( Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen. Engelstein, M; Kuhl, H; Mäenpää, J; Mattila, L; Mustonen, M; Rees, MC, 2004)	0.54
" DMPA-SC was well-tolerated and adverse events were similar to those reported previously with Depo-Provera IM."	( Contraceptive efficacy and safety of DMPA-SC. Bode, FR; Jain, J; Jakimiuk, AJ; Kaunitz, AM; Ross, D, 2004)	0.32
" All regimens were well tolerated with a low frequency of adverse effects, mostly occurring within the first two years."	( Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. Heikkinen, J; Timonen, U; Vaheri, R, 2004)	0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"Results suggest that drospirenone possesses a generally well-accepted side effect profile and resembles comparator oral progestogens in conferring endometrial protection with no significant effect on weight."	( A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. Shulman, LP, 2006)	0.54
" The findings demonstrate an urgent need for a clear, balanced approach to advising health professionals on how to respond to new findings about adverse effects of contraceptives."	( How do health care professionals respond to advice on adverse side effects of contraceptive methods? The case of Depo Provera. Glasier, A; Wellings, K; Yan, Y, 2007)	0.34
"HIV-infected women on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation."	( Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)	0.63
" Nine Grade 3 or 4 adverse events occurred in seven subjects; none were judged related to DMPA."	( Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)	0.63
" Secondary measures indicated that both botanicals were safe as administered."	( Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Banuvar, S; Bolton, JL; Epstein, G; Farnsworth, NR; Geller, SE; Hedayat, S; Krause, EC; Nikolic, D; Pauli, GF; Piersen, CE; Shulman, LP; van Breemen, RB; Zhou, Y, )	0.13
" Safety monitoring indicated that chemically and biologically standardized extracts of black cohosh and red clover were safe during daily administration for 12 months."	( Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Banuvar, S; Bolton, JL; Epstein, G; Farnsworth, NR; Geller, SE; Hedayat, S; Krause, EC; Nikolic, D; Pauli, GF; Piersen, CE; Shulman, LP; van Breemen, RB; Zhou, Y, )	0.13
"The add-back therapy that consists of an estradiol patch and oral medroxyprogesterone acetate is effective and safe treatment for endometriosis."	( [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis]. Chen, X; Hu, WG; Hua, KQ; Wang, YQ; Zhang, SF; Zhu, J, 2009)	0.81
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" BZA/CE treatment was generally safe and well tolerated."	( Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Chines, AA; Komm, BS; Mirkin, S; Pan, K, 2013)	0.39
"Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases."	( Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? Bhavnani, BR; Stanczyk, FZ, 2014)	2.3
" Similar contraceptive efficacy, weight change, bleeding patterns and occurrence of other adverse effects among obese and nonobese DMPA-SC users were observed."	( The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Dragoman, MV; Gaffield, ME, 2016)	0.69
" foetida extract is safe and effective for the treatment of menopausal symptoms in postmenopausal women."	( Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women. Deng, Y; Gao, L; Sun, A; Wang, Y; Xue, W; Zheng, T; Zuo, H, 2018)	0.48
" A minority of respondents correctly classified the progestin-only pill, depot medroxyprogesterone acetate, the etonogestrel implant, the levonorgestrel intrauterine system and the copper intrauterine device as safe to use during lactation [14/56 (25%), 24/56 (43%), 27/56 (48%), 19/55 (35%) and 9/55 (16%), respectively]."	( An exploratory study of the perception of contraceptive safety and impact on lactation among postpartum nurses at Women and Infants Hospital in 2017. Allen, RH; Cohen, KE; Has, P; Matteson, KA, 2019)	0.74
" We compared the proportion of providers reporting select contraceptive methods as safe for women with specific characteristics or medical conditions before and after the USMEC release and conducted multivariable logistic regression to adjust for provider characteristics."	( Changes in US health care provider attitudes related to contraceptive safety before and after the release of National Guidance. Curtis, KM; Folger, SG; Morgan, IA; Whiteman, MK; Zapata, LB, 2019)	0.51
"For the following select characteristics for which the USMEC classifies specific contraceptive methods as safe (Category 1 or 2), a significantly (p<."	( Changes in US health care provider attitudes related to contraceptive safety before and after the release of National Guidance. Curtis, KM; Folger, SG; Morgan, IA; Whiteman, MK; Zapata, LB, 2019)	0.51
"Background and objectives: Abnormal uterine bleeding is a significant clinical and gynaecological concern that necessitates its safe and effective treatment."	( Evaluation of the Safety and Efficacy of Ormeloxifene, a Selective Estrogen Receptor Modulator and Medroxyprogesterone Acetate in Women with Non-Structural Abnormal Uterine Bleeding: A Randomized Clinical Trial. Ali, T; Almuqbil, M; Alshehri, AM; Alshehri, S; Amin, F; Ara, R; Bader, GN; Hamid, L; Malik, A; Mir, SA; Shakeel, F; Wani, SUD, 2022)	0.94

Excerpt	Reference	Relevance
" Following oral administration MPA is rapidly transferred from the gastrointestinal tract to the blood circulation with a half-life of the absorption process of 15-30 min."	( Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. Johansen, PB; Johansson, ED; Rasmussen, SN, 1986)	1.71
" Model-independent pharmacokinetic analysis (statistical moment theory) revealed a significant dependence of plasma clearance and mean residence time on the dose administered in both conditions."	( Medroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits. Camaggi, CM; Comparsi, R; Pannuti, F; Strocchi, E, 1987)	1.72
" While the results from all centres indicated that the four preparations were all effective in inhibiting ovulation for at least one month, there were marked between centre differences in pharmacokinetic profiles."	( A multicentered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and of DepoProvera. World Health Organization Task Force on Long-acting Systemic Agents for Fertility Regulation. Garza-Flores, J; Hall, PE; Koloszar, S; Konsayreepong, R; Kovacs, L; Perez-Palacios, G; Rodriguez, V; Tang-Keow, P; Virutamasen, P, 1987)	0.27
"The pharmacokinetic and bioavailability properties of medroxyprogesterone acetate (MPA) after single PO and IM doses in man were used as a basis to predict, on a theoretical pharmacokinetic basis, the blood level profile of the drug during repeated dose administration with various dosage schedules."	( Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Battaglia, A; Bernardo, G; Brunner, K; Cavalli, F; Ganzina, F; Goldhirsch, A; Isetta, AM; Robustelli della Cuna, G; Sacchetti, G; Tamassia, V, 1982)	0.75
" AUC and Cmax values were not dose-linear over the dosage range studied; indicative of the self-induced metabolism of MPA."	( Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Dey, M; Enever, R; Latta, D; Smith, D; Weierstall, R, 1993)	0.55
" There were no clear relationships between the oral dose and the MPA peak concentration (Cmax), area under the time versus concentration curve (AUC), or mean Css min."	( Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. Fujii, H; Igarashi, T; Imoto, S; Itoh, K; Kohagura, M; Ohtsu, T; Sasaki, Y; Wakita, H, 1998)	0.56
"To provide pharmacokinetic data for a safety evaluation of long-term use of the monthly injectable Cyclofem (25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate), 9 fertile Chinese women 27-34 years of age were enrolled in a 12-month clinical study."	( Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. Han, XJ; Sang, GW; Shao, QX; Weng, LJ; Zhou, XF, 1998)	0.83
" A simple pharmacokinetic model, essentially a modification of the single compartment model with first-order absorption and elimination, is developed to describe the time course of glucose concentration and the associated insulin response."	( Uising WinBUGS to fit nonlinear mixed models with an application to pharmacokinetic modelling of insulin response to glucose challenge in sheep exposed antenatally to glucocorticoids. Challis, JR; Gurrin, LC; Hazelton, ML; Moss, TJ; Newnham, JP; Sloboda, DM, 2003)	0.32
"Forty-six postmenopausal women from two essentially similar pharmacokinetic studies were divided into three age categories: under 60 years (n = 15), between 60 and 65 years (n = 18) and over 65 years (n = 13)."	( Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. Järvinen, A; Kainulainen, P; Kela, M; Nikkanen, H; Nissilä, M, 2004)	0.59
"No statistically significant differences were observed in the peak concentration (Cmax), time to peak (t(max)), AUC or elimination half-life for estradiol or MPA between the different age groups."	( Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. Järvinen, A; Kainulainen, P; Kela, M; Nikkanen, H; Nissilä, M, 2004)	0.59
" The results suggest that from the pharmacokinetic point of view the relationship between estradiol and MPA dose to be used in elderly could be different from that in younger postmenopausal women, while no pharmacokinetic reasons to use lower estradiol doses in the elderly were observed."	( Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. Järvinen, A; Kainulainen, P; Kela, M; Nikkanen, H; Nissilä, M, 2004)	0.59
"Using an optimized pharmacokinetic design, this study indicated men exhibit significantly higher zidovudine-monophosphate and zidovudine-triphosphate exposure following zidovudine oral administration, having implications for drug toxicity and overall tolerance of zidovudine therapy."	( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006)	0.33
"A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs."	( Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg). Garza-Flores, J; Godínez-Victoria, M; Hernádez-Munguía, IA; Lara-Ricalde, R; Lujan, M; Padilla, A; Sierra-Ramírez, JA; Velázquez-Ramírez, N, 2011)	0.58
" We evaluated the pharmacokinetic profile of medroxyprogesterone acetate (MPA) following injection of Depo-SubQ Provera 104 in the upper arm, a preferred injection site in developing countries."	( Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. Archer, DF; Combes, SL; Dorflinger, LJ; Halpern, V; Weiner, DH, 2014)	0.93
"To explore the relationship between medroxyprogesterone acetate (MPA) pharmacokinetic (PK) parameter estimates and weight gain."	( A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. Bonny, AE; Gothard, DM; Lange, HL; Reed, MD; Rogers, LK, 2014)	0.99
" PK parameters were calculated: maximum MPA concentration (Cmax, ng/mL), time to Cmax (Tmax, days) and elimination rate constant (ng/mL/day)."	( A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. Bonny, AE; Gothard, DM; Lange, HL; Reed, MD; Rogers, LK, 2014)	0.71
" Areas covered: This review aims to offer the reader a complete overview of pharmacokinetic (PK) and clinical efficacy of progestins for the treatment of endometriosis."	( Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Barra, F; Ferrero, S; Scala, C, 2018)	0.48
" We used mixed effects linear regression models to compare pharmacodynamic measures for each participant at predrug baseline, after PrEP alone, and after PrEP and DMPA."	( Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women. Achilles, SL; Chen, BA; Hendrix, CW; Marzinke, MA; Meyn, LA; Tarleton, J, 2020)	0.81
" A pooled population pharmacokinetic analysis with 744 plasma medroxyprogesterone acetate concentrations from 138 women treated with depot medroxyprogesterone and antiretroviral/antituberculosis treatment across three clinical trials was performed."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	1.11

Excerpt	Reference	Relevance
"A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out."	( [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992)	0.51
"We compared the effects on hemostatic variables of transdermal estradiol and oral equine conjugated estrogens (CEE), both combined with medroxyprogesterone acetate, in 40 postmenopausal women, 22 randomly allocated to transdermal estradiol and 18 to CEE."	( Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Bertolli, V; Boschetti, C; Cortellaro, M; Della Volpe, A; Nencioni, T; Zanussi, C, 1991)	0.69
"Forty-eight patients with advanced or recurrent breast cancer unresponsive to other therapies were treated orally with medroxyprogesterone acetate (MPA) 1,200 mg/day alone (Group A: 28 patients) or in combination with cyclophosphamide (CPA) 100 mg/day (Group B: 20 patients)."	( [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer]. Aikawa, T; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1991)	0.79
" Synergistic activities were produced with TAM combined with either cisplatin or doxorubicin."	( The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Berens, ME; Duckett, Y; Geisinger, KR; Kute, TE; Morgan, TM; Welander, CE, 1990)	0.28
" Combined with an appropriate P complement, it could be a useful contraceptive approach."	( Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach. Faure, N; Lemay, A, 1986)	0.27
" Some of the testosterone-supplemented rats were treated with medroxyprogesterone acetate (MPA) alone or in combination with epirubicin hydrochloride."	( Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma. Damber, JE; Landström, M; Tomić, R, 1987)	0.92
" In order to test whether IFN therapy combined with hormones would result in higher response rates we compared single agent IFN therapy with a combined therapy of rIFN alpha 2C plus medroxyprogesterone acetate (MPA) in a randomized multicenter trial."	( Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. Aulitzky, W; Gottwald, A; Hautmann, R; Messerer, D; Moormann, JG; Porzsolt, F; Rasche, H; Schumacher, K; Sparwasser, H; Stockamp, K, 1988)	0.68
" In conclusion, intermittent administration of appropriate LH-RH agonist dosing in combination with a progestogen would effectively block ovulation while preserving adequate cyclic estradiol secretion and could be an alternative contraceptive approach."	( Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding. Faure, N; Fazekas, AT; Labrie, F; Lemay, A, 1985)	0.27
" In conclusion, intermittent administration of appropriate LH-RH agonist dosing in combination with a progestogen would effectively block ovulation while preserving adequate cyclic estradiol secretion and could be an alternative contraceptive approach."	( Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding. Faure, N; Fazekas, AT; Labrie, F; Lemay, A, 1985)	0.27
"To assess prospectively the effect on bleeding patterns, transformation of the endometrium, and rate of endometrial hyperplasia of transdermal norethisterone acetate when administered sequentially in combination with transdermal estradiol (E2), and to compare it to a regimen using oral medroxyprogesterone acetate."	( Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. Boyd, ME; Colgan, TJ; Ferenczy, A; Fugere, P; Lorrain, J; Ross, AH, 1993)	0.46
"6 mg/month combined with continuous oestradiol valerate 1 mg daily and medroxyprogesterone acetate 5 mg daily."	( An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy. Beard, RW; Cooper, S; Gangar, KF; Rae, T; Rogers, V; Saunders, D; Stones, RW, 1993)	0.52
"Our purpose was to evaluate the efficacy and safety of depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol in the long-term treatment of pelvic pain in women with endometriosis."	( Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Cortesi, I; Crosignani, PG; De Giorgi, O; Oldani, S; Panazza, S; Vercellini, P, 1996)	1.02
"15 mg) combined with oral danazol 50 mg a day for 21 days of each 28-day cycle."	( Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Cortesi, I; Crosignani, PG; De Giorgi, O; Oldani, S; Panazza, S; Vercellini, P, 1996)	0.77
"The tolerability and effectiveness of depot medroxyprogesterone acetate (DMPA), compared with an oral contraceptive (OC) combined with low-dose danazol, in the long-term treatment of pelvic pain in women with endometriosis were evaluated in a randomized clinical trial."	( Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Cortesi, I; Crosignani, PG; De Giorgi, O; Oldani, S; Panazza, S; Vercellini, P, 1996)	1.04
"To compare the effect of transdermal estradiol-17 beta and oral conjugated equine estrogen when combined with an oral progestin on quality of life in post-menopausal women."	( A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Charles, J; Dunn, EV; Franssen, E; Hilditch, JR; Lewis, J; Norton, P; Peter, A; Ross, AH; van Maris, B, 1996)	0.29
"The objective of this study was to determine the arterial responses to plasma lipid lowering alone or in combination with (1) estrogen replacement therapy or (2) hormone replacement therapy in surgically postmenopausal female monkeys with preexisting atherosclerosis."	( Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Adams, MR; Clarkson, TB; Golden, DL; Register, TC, 1998)	0.54
" Hormone replacement therapy combined with simvastatin is well tolerated and extremely effective, as the two therapies seem to be additive."	( The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. Kyriakides, ZS; Sbarouni, E, 1998)	0.3
" Nonetheless, observational studies report no differences in risk for clinical cardiovascular events between users of unopposed estrogen and users of estrogen combined with synthetic progestin."	( Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Choi, IS; Hwang, HY; Jin, DK; Kang, MH; Kim, DS; Kim, W; Koh, KK; Lee, SK; Shin, EK; Yang, SH, 2001)	0.31
"To observe the efficacy of estradiol valerate (E(2)V) combined with medroxyprogesterone acetate (MPA) in prevention of bone loss among postmenopausal women with osteopenia."	( [Prevention of bone loss by estradiol valerate combined with medroxyprogesterone acetate among postmenopausal women with osteopenia]. Chen, F; Lin, S; Lu, J; Shen, Y; Yu, W; Zhang, L; Zhang, Y, 2002)	0.79
"Administration of E(2)V I mg/d combined with MPA 2 mg/d is an optional regimen for postmenopausal women with intact uterine."	( [Prevention of bone loss by estradiol valerate combined with medroxyprogesterone acetate among postmenopausal women with osteopenia]. Chen, F; Lin, S; Lu, J; Shen, Y; Yu, W; Zhang, L; Zhang, Y, 2002)	0.56
"Conjugated equine estrogen alone or combined with medroxyprogesterone acetate lowered homocysteine levels in postmenopausal women."	( Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. Hsu, SC; Lee, JN; Liu, CM; Long, CY; Tsai, EM; Yang, CH, 2005)	0.83
"To evaluate the benefits and risks of hormone replacement therapy (HRT) combined with methyltestosterone (MT) in postmenopausal women with sexual dysfunction."	( The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Baracat, EC; de Lima, GR; de Paula, FJ; Haidar, MA; Soares, JM, 2007)	0.34
" We hypothesized that testosterone (T) transdermal gel (T gel) could be combined with a depot formulation of the progestin, depomedroxyprogesterone acetate (DMPA), with or without the potent GnRH antagonist, acyline, to suppress spermatogenesis conveniently, rapidly, and reversibly."	( Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. Amory, JK; Anawalt, BD; Bremner, WJ; Brockenbrough, AT; Irwig, MS; Matsumoto, AM; Page, ST, 2006)	0.82
"To evaluate effects and safety of gonadotrophin-releasing hormone agonist (GnRH-a) combined with transdermal estradiol and medroxyprogesterone acetate in the treatment of endometriosis."	( [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis]. Chen, X; Hu, WG; Hua, KQ; Wang, YQ; Zhang, SF; Zhu, J, 2009)	0.78
" Based on the concentration of MPA in human liver, the magnitude of in vivo drug-drug interaction (DDI) was predicted."	( Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions. Fang, ZZ; Huang, T; Yang, L, 2010)	0.65
" This study, in combination with previous research, indicates that hormone effects cannot be generalized across tasks, age, or duration, and long-term estrogen in combination with MPA can be beneficial for some tasks."	( Long-term replacement of estrogen in combination with medroxyprogesterone acetate improves acquisition of an alternation task in middle-aged female rats. Chisholm, NC; Juraska, JM, 2012)	0.63
"Drugs most likely to interact with combined oral contraceptives, transdermal and implant contraceptives include protease inhibitors, the NNRTIs efavirenz and nevirapine, and cobicistat-boosted elvitegravir."	( Drug interactions between antiretrovirals and hormonal contraceptives. Hills-Nieminen, C; Tseng, A, 2013)	0.39
"We conducted an open-label, steady-state pharmacokinetic (PK) study of drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV) (LPV/r) among 24 HIV-infected women and compared the results to those for HIV-infected women receiving DMPA while on no antiretroviral therapy or on nucleosides only (n = 14 subjects from the control arm of AIDS Clinical Trials Group [ACTG] study 5093)."	( Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the Aweeka, F; Cohn, SE; Cramer, Y; Klingman, KL; Livingston, E; Luque, AE; Park, JG; Watts, DH; Weinberg, A, 2015)	1.11
" The aim of this work was to study the effect of different concentrations of MPA combined with 17β-estradiol (17β-E2) on proliferation, migration, and apoptosis of EPCs in vitro."	( Effect of different concentrations of medroxy-progesterone acetate combined with 17β-estradiol on endothelial progenitor cells. Lai, Y; Linghu, LJ; Liu, LH; Liu, YF; Zhang, Y, 2015)	0.42
"Proliferation tests (MTT analysis) and migration assay of EPCs, isolated from bone marrow of canine, were performed to detect their response to different concentrations of MPA combined with 17β-E2 (1 × 10(-8) mol/L)."	( Effect of different concentrations of medroxy-progesterone acetate combined with 17β-estradiol on endothelial progenitor cells. Lai, Y; Linghu, LJ; Liu, LH; Liu, YF; Zhang, Y, 2015)	0.42
" The higher concentration of MPA (≥ 10(-4) mol/L) combined with 17β-E2 had a significant inhibitory effect on EPC growth, arresting it in the S phase."	( Effect of different concentrations of medroxy-progesterone acetate combined with 17β-estradiol on endothelial progenitor cells. Lai, Y; Linghu, LJ; Liu, LH; Liu, YF; Zhang, Y, 2015)	0.42
" However, high concentration of MPA combined with 17β-E2 inhibited a variety of biological functions of EPCs."	( Effect of different concentrations of medroxy-progesterone acetate combined with 17β-estradiol on endothelial progenitor cells. Lai, Y; Linghu, LJ; Liu, LH; Liu, YF; Zhang, Y, 2015)	0.42
" Group I consisted of 15 patients who were treated with depot MPA combined with GnRH analog."	( Gonadotropin-Releasing Hormone Analog Combined with Depot Medroxyprogesterone Acetate in the Management of Endometrial Hyperplasia A Prospective Randomized Clinical Study. Demir Karakilic, I; Guler, I; Karabacak, N; Karabacak, O; Korucuoglu, U, 2016)	0.68
"Prospectively recruited postmenopausal women, <45 years, were randomised to one of two treatment arms for 12-months: cyclical micronised progesterone or medroxyprogesterone acetate in combination with transdermal oestradiol."	( A direct comparison of women's perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age. Cardozo, L; Hamoda, H; Mittal, M; Panay, N; Savvas, M; Supramaniam, PR, 2020)	0.98
"The acceptability of both regimens was high despite adverse effects, but tolerability of transdermal oestradiol combined with micronised progesterone appeared to be better with fewer women reporting psychological concerns."	( A direct comparison of women's perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age. Cardozo, L; Hamoda, H; Mittal, M; Panay, N; Savvas, M; Supramaniam, PR, 2020)	0.78
" As medroxyprogesterone acetate is a cytochrome P450 (CYP3A4) substrate, drug-drug interactions (DDIs) with antiretroviral or antituberculosis treatment may lead to subtherapeutic medroxyprogesterone acetate concentrations (< 0."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	1.43
"To compare the impact of micronized progesterone (MP) or medroxyprogesterone acetate (MPA) in combination with transdermal estradiol (t-E2) on traditional coagulation factors and thrombin generation parameters in postmenopausal women diagnosed with premature ovarian insufficiency or early menopause."	( The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial. Arya, R; Cardozo, L; Chitongo, P; Hamoda, H; Mittal, M; Panay, N; Savvas, M; Supramaniam, PR, 2022)	1.23
"Thrombin generation parameters did not significantly change from baseline after 3-months duration for either progestogen component when combined with t-E2, unlike the traditional coagulation factors."	( The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial. Arya, R; Cardozo, L; Chitongo, P; Hamoda, H; Mittal, M; Panay, N; Savvas, M; Supramaniam, PR, 2022)	0.99

Excerpt	Reference	Relevance
"The bioavailability of three formulations of medroxyprogesterone acetate (MPA) was assessed in 30 healthy male volunteers in a three-way, open-label, cross-over-designed trial."	( Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. Pollock, SR; Stalker, DJ; Welshman, IR, )	0.72
" Based on a pilot study, an open, randomized, crossover trial has been performed on 22 breast and endometrial cancer patients to evaluate the relative bioavailability of this new oral formulation (200-mg sachet, twice daily) as compared with a standard formulation (Farlutal, 500-mg tablet, twice daily)."	( Improved bioavailability of a new oral preparation of medroxyprogesterone acetate. Benedetti, MS; Efthymiopoulos, C; Etienne, MC; Frenay, M; Hurteloup, P; Milano, G; Montcuquet, P; Namer, M; René, N; Vo Van, ML, 1991)	0.53
"Serum levels of cortisol (C), androstenedione (A), dehydroepiandrosterone (D), estrone (E1) and estradiol (E2) were chosen as parameters to compare the bioavailability of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in postmenopausal patients with advanced breast cancer."	( Adrenal steroids as parameters of the bioavailability of MA and MPA. Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990)	0.47
" The in vitro dissolution rates of MPA from the tablet formulations were determined and compared with the results of the bioavailability studies, indicating that a rapid dissolution rate as well as the particle size of MPA are two important factors to ensure optimal absorption of MPA from the gastrointestinal tract."	( Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. Johansen, PB; Johansson, ED; Rasmussen, SN, 1986)	1.71
" Relative bioavailability of preparations should be considered when prescribing or assessing treatment results when MPA is used."	( Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations. Chapman, D; Mould, GP; Rostom, AY; Stockdale, AD, 1987)	1.72
"The pharmacokinetic and bioavailability properties of medroxyprogesterone acetate (MPA) after single PO and IM doses in man were used as a basis to predict, on a theoretical pharmacokinetic basis, the blood level profile of the drug during repeated dose administration with various dosage schedules."	( Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Battaglia, A; Bernardo, G; Brunner, K; Cavalli, F; Ganzina, F; Goldhirsch, A; Isetta, AM; Robustelli della Cuna, G; Sacchetti, G; Tamassia, V, 1982)	0.75
"The relative bioavailability of an orally administered aqueous suspension of medroxyprogesterone acetate (MPA) intended for intramuscular injection (Depo-Provera) was determined in relation to orally administered tablets."	( The bioavailability of an orally administered medroxyprogesterone acetate suspension. Albert, KS; Antal, EJ; Gillespie, WR, 1983)	0.75
" Extremely high interpatient variation in bioavailability is present with both administration routes."	( Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients. Angelelli, B; Camaggi, CM; Costanti, B; Ferrari, P; Giovannini, M; Pannuti, F; Strocchi, E; Zebini, E, 1983)	1.71
"The influence of injection volume on the absorption and bioavailability of medroxyprogesterone acetate (MPA) was studied."	( Effect of injection volume on the bioavailability of sterile medroxyprogesterone acetate suspension. Albert, KS; Antal, EJ; Gillespie, WR; Wright, CE, )	0.6
"Twenty-six female patients with breast cancer participated in an open, randomized, cross-over study comparing single dose bioavailability of a recently developed oral medroxyprogesterone acetate (MPA) formulation (200 mg sachet where MPA is loaded in a polyvinylpyrrolidone cross-linked polymer, MPA/PVP) with the standard formulation (500 mg tablet)."	( Bioavailability of a new oral formulation of medroxyprogesterone acetate compared with the standard formulation: a single dose randomized study. Brunsgaard, N; Edwards, DM; Jakobsen, P; Kjaer, M; Strolin-Benedetti, M, 1993)	0.74
" The oral absorption of MPA in dogs appears to be dose-linear over the dosage range studied, and the absolute bioavailability was estimated at 27 per cent."	( Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Dey, M; Enever, R; Latta, D; Smith, D; Weierstall, R, 1993)	0.55
" The bioavailability of MPA and plasma concentrations of progesterone and luteinizing hormone (LH) after mating were monitored following a single meal containing MPA (1000 mg) in entire does (n = 4); the response to gonadotrophin-releasing hormone (GnRH; 250 ng) was also observed in MPA-treated, ovariectomized does (n = 6)."	( Anti-fertility effects of oral medroxyprogesterone acetate in rabbits. Barrell, GK; Oguge, NO, 1996)	0.58
"Because natural progesterone is poorly absorbed and rapidly metabolized, synthetic derivatives of progesterone, such as medroxyprogesterone acetate (MPA), are used in combination with estrogen in hormone replacement therapy."	( Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Rosner, A; Ryan, N, 2001)	0.75
" Loss of endogenous estrogen also leads to reduced bioavailability of endothelium-derived nitric oxide."	( Vasomotor and vascular effects of hormone replacement therapy. Ganz, P, 2002)	0.31
" However, a significant trend towards higher MPA concentrations and bioavailability was observed with increasing age."	( Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. Järvinen, A; Kainulainen, P; Kela, M; Nikkanen, H; Nissilä, M, 2004)	0.59
" The effect of progestogens on IGF bioavailability could be an important determinant of the longer-term risks of specific HRT preparations by opposing the potentially beneficial effects of CEE alone on cardiovascular risk."	( Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Anderson, S; Durrington, PN; Gibson, MJ; Heald, A; Kaushal, K; Redpath, M; Selby, PL, 2005)	0.33
" MPA has a low oral bioavailability because of extensive metabolism; however, its metabolism was poorly documented."	( Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Gao, Y; Ge, GB; Li, W; Liu, HT; Liu, HX; Liu, Y; Sun, J; Wang, LM; Yang, L; Zhang, JW; Zhang, YY; Zhao, JY, 2008)	0.58
" Moreover, the area under the curve of EE and MPA revealed an increase in bioavailability after transdermal administration as compared to oral route."	( Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. Agrawal, SS; Pruthi, JK, 2011)	0.59
" Poor bioavailability limited exposure despite dose escalation."	( A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Althouse, SK; Carey, L; Jones, DR; Kimmick, G; Merino, MJ; Miller, KD; Nabell, L; Rugo, H; Steeg, PS, 2014)	0.73
" An alternative approach, particularly considering agents with relatively low toxicity, such as orally bioavailable fluoropyrimidines, is to continue chemotherapy until disease progression."	( Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer. Makris, A; Miles, D; Sutherland, S, 2016)	0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" DMPA when given in proper dosage and time reverted the condition."	( Study of the effects of a long acting injectable-progesterone on the ovarian and uterine histomorphology of the androgenised female rats of Long-Evans strain. Ahmed, F; Bari, MA, 1979)	0.26
" Dosage adjustment was allowed in one centre."	( Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy. Chambers, HM; Kirkgard, Y; MacLennan, A; MacLennan, AH; O'Neill, S; Wenzel, S, 1992)	0.28
" Where dosage adjustment was allowed, almost all side effects were eliminated."	( Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy. Chambers, HM; Kirkgard, Y; MacLennan, A; MacLennan, AH; O'Neill, S; Wenzel, S, 1992)	0.28
" All cases of simple or complex hyperplasia showed a regression after increased MPA dosage treatment (20 mg)."	( Endometrial response in sequential cyclic therapy assessed with associated hysteroscopy and histology. Baracchini, P; Bernardini, L; de Cecco, L; Ferraiolo, A; Fulcheri, E; Gerbaldo, D; Pescetto, G, 1992)	0.28
" Meanwhile, Provera exerted dose-response inhibition on both AE7 and ECC-1 cell lines."	( Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry. Angioli, R; Averette, HE; Donato, D; Nguyen, HN; Penalver, M; Perras, J; Ramos, R; Sevin, BU; Voigt, W, 1992)	0.28
" The results indicate that at a dosage of 3-4."	( The effects of medroxyprogesterone acetate and ethinylestradiol on hemogram, prostate, testes, and semen quality in normal dogs. Bamberg-Thalén, B; Linde-Forsberg, C, 1992)	0.64
" There were no differences in terminal elimination rate constants among the dosage forms."	( Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. Pollock, SR; Stalker, DJ; Welshman, IR, )	0.46
" In the first approach medroxyprogesterone dosage increased up to 400 mg a day, achieved better results in curative as well as adjuvant treatment of advanced or early gynecologic cancers."	( New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies. Bonte, J; Vanderstappen, D, 1992)	0.59
" Research on combination norethynodrel-containing products revealed that the dosage was too high."	( Oral contraception: a review. Edgren, RA, 1991)	0.28
" There was no significant difference in the suppression of spermatogenesis between the two dosage regimens."	( Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men. Pangkahila, W, 1991)	0.28
"25-mg dosage of conjugated estrogens."	( Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Clisham, PR; de Ziegler, D; Judd, HL; Lozano, K, 1991)	0.28
" Doubling the dose of either drug did not enhance hormone suppression, indicating that the drug dosage is maximally suppressive."	( Adrenal steroids as parameters of the bioavailability of MA and MPA. Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990)	0.28
" Prolonged hormonal and incorrect treatments, mainly for too high dosage and absence of association with progesterone, assumption of oestrogens, can cause the growth of mammary tumours."	( [Male transsexualism and hormonal therapy: radiologic pictures of the breast]. Bocchini, R; Cavallotti, GP; Genovese, MG; Godano, A; Grassi, G; Massara, D, 1990)	0.28
" Many investigators have reported that progestogen with high dosage shows a good response to advanced endometrial cancer."	( [Therapy of advanced endometrial cancer]. Okada, H; Yamamoto, T, 1990)	0.28
" No increases in nongenital malformations were noted at any evaluated MPA dosage level."	( Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate. Brent, RL; Buck, S; Carbone, JP; Figurska, K, 1990)	0.48
" Attempts to further enhance the role of progestins have centered on dosage escalation, based on European data suggesting a dose-response effect."	( Current status of high-dose progestins in breast cancer. Abrams, JS; Aisner, J; Parnes, H, 1990)	0.28
" The response rate and side-effect data from a pilot study, which used the old formulation Provera Tablets 100 mg at a dosage of 800 mg/day in 28 patients with recurrent breast cancer after treatment with tamoxifen, are compared with those from another study in which 59 similar patients received 800 mg/day of new formulation Provera Tablets 200 mg."	( Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio? Bates, T; Bozzino, JM; Brock, JE; Clarke, DG; Durrant, KR; Evans, RG; Roberts, JT; Tobias, JS, 1990)	0.52
"After initial surgery, 240 pre-, peri- or postmenopausal patients with early node-negative breast carcinoma were randomized to receive either no hormone therapy or adjuvant therapy with medroxyprogesterone acetate at high dosage (HD-MPA; 500 mg IM per day times 28 or 500 mg intramuscularly (i."	( Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I). Baudoux, A; Beauduin, M; Bunescu, U; Dehasque, N; Dewasch, L; Focan, C; Lobelle, JP; Longeval, E; Majois, F; Mazy, V, 1989)	0.75
" Intra-arterial injection of this drug alone or in conjunction with OK-432 can also be used, even though further studies will be required to determine the optimum dosage and reduce side effects."	( Experimental local administration of CDDP to in vitro models of gynecological malignant tumors transplanted into nude mice (compared with medroxyprogesterone acetate orally administered). Hashii, K; Kamitani, N; Kanto, T; Mori, T; Natsuyama, S; Tateyama, I; Tominaga, T, 1989)	0.48
" Medroxyprogesterone acetate was given orally to the 6 study subjects over a 10-day period in an incremental dosage to mimic the luteal phase."	( Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Berga, SL; Yen, SS, 1989)	1
"; USA) was administered intramuscularly on day 27 (+/- 2) of gestation to three dosage groups of pregnant baboons."	( Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus). Carroad, E; Hendrickx, AG; Prahalada, S, 1985)	0.52
" Cyproterone acetate allows differentiated treatment according to the various grades of hirsutism by modification of dosage and application."	( [The concept of the causal therapy of hirsutism]. Schmidt, JB, 1986)	0.27
" Thirty-four received treatment B: tamoxifen 30 mg per day and after relapse, high dosage of MPA alone."	( [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications]. Bonichon, F; Chauvergne, J; Durand, M; Mauriac, L, 1986)	0.51
" MPA was administered at a dosage of 1,200mg orally per day."	( [Phase II study of medroxyprogesterone acetate in advanced breast cancer]. Horikoshi, N; Imajo, K; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Ozeki, H; Ueno, K, 1986)	0.6
" The most appropriate dosage regimen for potential contraception was 200 micrograms/12 hours for 21 days because it was associated with small follicles and serum E2 was in the range of control cycles."	( Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach. Bastide, A; Faure, N; Lemay, A, 1987)	0.27
" The most appropriate dosage regimen for potential contraception is 200 mcg/12 hours for 21 days."	( Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach. Bastide, A; Faure, N; Lemay, A, 1987)	0.27
" This even occurs with those methods which do not usually suppress ovulation, but the disturbance is generally less severe with lower dosage systems."	( Menstrual changes associated with progestogen-only contraception. Fraser, IS, 1986)	0.27
" No differences between the 3 treatment arms were observed except for medroxy-progesterone acetate, which showed less therapeutic effect in the dosage used."	( Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer. Debruyne, FM, 1988)	0.27
" The peripheral serum levels of MPA exhibit enormous inter- and intraindividuell variations and only the high dosage schemes yield levels above 90 ng/ml which are claimed necessary by some authors."	( [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology]. Egarter, C; Eppel, W; Husslein, P; Salzer, H; Spona, J, 1988)	0.79
" A linear increase of cytosolic estrogen receptor concentration occurred over the dosage range of conjugated equine estrogen."	( Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Gibbons, WE; Lobo, RA; Mishell, DR; Moyer, DL; Roy, S, 1986)	0.27
" In conclusion, intermittent administration of appropriate LH-RH agonist dosing in combination with a progestogen would effectively block ovulation while preserving adequate cyclic estradiol secretion and could be an alternative contraceptive approach."	( Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding. Faure, N; Fazekas, AT; Labrie, F; Lemay, A, 1985)	0.27
" In conclusion, intermittent administration of appropriate LH-RH agonist dosing in combination with a progestogen would effectively block ovulation while preserving adequate cyclic estradiol secretion and could be an alternative contraceptive approach."	( Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding. Faure, N; Fazekas, AT; Labrie, F; Lemay, A, 1985)	0.27
" It is concluded that, while the priming action exerted by E2B on PgRs might explain the potentiating effect shown by E2B on MPA activity, the synergism observed between TMX and MPA should be explained on an extrareceptorial basis, an induction on PgR synthesis by TMX not being evident at the dosage and priming time employed in this study."	( Effects of tamoxifen, estradiol benzoate and medroxyprogesterone acetate on the growth of DMBA-induced rat mammary carcinoma. Barbi, GP; Boccardo, F; Dandolo, G; De Menech, R; Guarneri, D; Moro, MG; Paganuzzi, M; Pino, G; Sanguineti, M; Zanardi, S, 1985)	0.53
" Repetitive endometrial biopsy is impractical, and ethical constraints limit the dosage and duration of administration for some steroids."	( Histologic response of normal human endometrium to steroid hormones in athymic mice. Mortel, R; Satyaswaroop, PG; Zaino, RJ, 1985)	0.27
" The results show a wide individual variation in plasma concentrations following similar dosing schedules--a finding reported by other workers."	( Simple high-performance liquid chromatographic method for the determination of medroxyprogesterone acetate in human plasma. Mould, G; Read, J; Stevenson, D, 1985)	0.5
"The pharmacokinetic and bioavailability properties of medroxyprogesterone acetate (MPA) after single PO and IM doses in man were used as a basis to predict, on a theoretical pharmacokinetic basis, the blood level profile of the drug during repeated dose administration with various dosage schedules."	( Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Battaglia, A; Bernardo, G; Brunner, K; Cavalli, F; Ganzina, F; Goldhirsch, A; Isetta, AM; Robustelli della Cuna, G; Sacchetti, G; Tamassia, V, 1982)	0.75
" Optimal dosage remains to be determined."	( A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer. Falkson, G; Falkson, HC, 1983)	0.55
" Mean steady-state serum concentrations of MPA were simulated from single-dose data to reflect those achieved after standard dosage regimens."	( Effect of injection volume on the bioavailability of sterile medroxyprogesterone acetate suspension. Albert, KS; Antal, EJ; Gillespie, WR; Wright, CE, )	0.37
" It has become evident that DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity than does cyproterone acetate, but severe cardiovascular complications did not differ between treatment groups."	( Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials. Schroeder, FH, 1984)	0.27
" There is a tendency towards an increased response-rate with increased dosage of progestin, in both endometrial and breast carcinoma, while the route of administration appears to be of minor importance."	( Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Kauppila, A, 1984)	0.27
"A high-pressure liquid chromatography method for the quantitation of hydroxyprogesterone caproate, medroxyprogesterone acetate, and progesterone in pharmaceutical dosage forms was developed."	( Quantitation of hydroxyprogesterone caproate, medroxyprogesterone acetate, and progesterone by reversed-phase high-pressure liquid chromatography. Das Gupta, V, 1982)	0.74
"Each study was reviewed for the design, number of subjects enrolled, duration of protocol, and type and dosage of medications used."	( Combined continuous hormone replacement therapy: a critical review. Adashi, EY; Langenberg, P; Udoff, L, 1995)	0.29
" Greater drop-out rate and greater incidence of side effects attributed to oestrogen in higher dosage group."	( A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Holland, EF; Smith, RN; Studd, JW; Zamblera, D, 1995)	0.29
" MPA was administrated intramuscularly at a dosage of 500 mg/week."	( Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Hofstetter, A; Kriegmair, M; Oberneder, R, 1995)	0.56
"This pilot study was conducted to establish the optimum oral dosage of medroxyprogesterone acetate (Provera) given daily in combination with a fixed dose of piperazine oestrone sulphate (Ogen), as hormone replacement therapy."	( Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes. Nand, SL; Webster, MA; Wren, BG, 1995)	0.77
" Using a double-masked design, the subjects were randomized to medroxyprogesterone acetate 10 mg/day for 14 days every 28 or 84 days, or the same dosage for 28 of 84 days."	( Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Fu, YS; Judd, HL; Schoenfeld, MJ; Voigt, BJ; Williams, DB, 1994)	0.53
" Women who developed this tumor on sequential therapy in general received less than the recommended guidelines for daily dosage and monthly duration of progestin."	( Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Barbuto, DA; Judd, HL; Karlan, BY; Lagasse, LD; Leuchter, RS; McGonigle, KF, 1994)	0.29
" This suggested that further study the interval and dosage of provera should be given with CEE3."	( [Effect of nylestriol on postmenopausal uterine endometrium]. Liu, JL, 1993)	0.29
" The oral absorption of MPA in dogs appears to be dose-linear over the dosage range studied, and the absolute bioavailability was estimated at 27 per cent."	( Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Dey, M; Enever, R; Latta, D; Smith, D; Weierstall, R, 1993)	0.55
" Clear dose-response effects on both type 1 and type 2 11 beta HSD activities were obtained in cells incubated with 10(-8) mol/liter E2 added together with MPA at concentrations that approximated circulating progesterone levels from the luteal phase (10(-9) mol/liter) through pregnancy (10(-7) mol/liter)."	( Expression of 11 beta-hydroxysteroid dehydrogenase during decidualization of human endometrial stromal cells. Arcuri, F; Lockwood, CJ; Monder, C; Schatz, F, 1996)	0.29
" The connection between the efficacy and dosage of the efficacy and period of therapy were observed."	( [Therapy of premenstrual syndrome with medroxyprogesterone acetate in various dosages]. Hörömpöli, C; Szántó, F, 1996)	0.56
" After dosage with 1000 mg MPA, plasma concentrations of MPA were detectable for eight days."	( Anti-fertility effects of oral medroxyprogesterone acetate in rabbits. Barrell, GK; Oguge, NO, 1996)	0.58
" HRT at the dosage utilized in the study did not seem influence the Lp(a) concentrations after 3 and 6 months."	( Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. Anelli, G; Capri, O; Galoppi, P; Lucani, G; Mazzarella, B; Perrone, G; Stefanutti, C; Vivenzio, A; Zichella, L, )	0.13
"Both transdermal and oral estrogens at medium dosage have a favorable influence on total cholesterol and LDL-cholesterol level of hypercholesterolemic menopausal women, but Lp(a) remains resistant to manipulation."	( Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. Anelli, G; Capri, O; Galoppi, P; Lucani, G; Mazzarella, B; Perrone, G; Stefanutti, C; Vivenzio, A; Zichella, L, )	0.13
"Our purpose was to compare the effects on fasting plasma lipoprotein lipids of adding low dosage C-19 continuous progestin (dl-norgestrel) versus conventional low-dosage continuous C-21 progestin (medroxyprogesterone acetate) to cyclic conjugated estrogen therapy."	( Effects of adding C-19 versus C-21 progestin to conjugated estrogen in moderately hypercholesterolemic postmenopausal women. Koval, JJ; Nisker, JA; Wolfe, BM, 1998)	0.49
" We also noted a significant dose-response relation between longer use of depot medroxyprogesterone acetate and decreased bone density levels in this age group (P < ."	( Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Barlow, WE; Ichikawa, LE; Lacroix, AZ; Ott, SM; Scholes, D, 1999)	0.79
"To compare compliance, symptom control, bleeding patterns, endometrial response, and lipid changes in postmenopausal women treated with transdermal E2 and a regimen of either intermittent or continuous dosing of progestin."	( Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Cano, A; Dueñas, JL; Tarín, JJ, 1999)	0.3
"Fourteen women dropped out of the intermittent dosing group and 13 dropped out of the continuous dosing group."	( Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Cano, A; Dueñas, JL; Tarín, JJ, 1999)	0.3
"To compare the effects of (i) continuous low dosage C-19 progestin (dl-norgestrel, NG) plus cyclical conjugated estrogen (CEE) versus (ii) continuous low dosage C-21 progestin [medroxyprogesterone acetate (MPA)] plus CEE on postmenopausal vaginal bleeding, mood and somatic, psychosomatic and psychological symptoms."	( Impact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen. Koval, JJ; Nisker, JA; Wolfe, BM, 1999)	0.5
" Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks (serum progesterone concentrations did not exceed 1 ng/mL)."	( Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Rahimy, MH; Ryan, KK, 1999)	0.57
" Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks."	( Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Rahimy, MH; Ryan, KK, 1999)	0.57
" IL-6 level was investigated in these patients dosed with 800 mg/day of MPA and in 17 postoperative nonrecurrent patients."	( An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Baba, K; Fukuda, M; Hamamoto, R; Matsuda, M; Matsuoka, Y; Miyayama, H; Mizumoto, T; Nagao, K; Nishimura, R; Yamashita, H, 2000)	0.54
"This study was designed to compare with placebo the dose-response of conjugated equine oestrogen (CEE) on blood pressure in hypertensive postmenopausal women."	( Dose response effect of conjugated equine oestrogen on blood pressure in postmenopausal women with hypertension. Harvey, PJ; Molloy, D; Upton, J; Wing, LM, 2000)	0.31
"Most women aged at least 55 years can safely switch their HRT regimen from standard dosage HRT to low-dosage estrogen opposed by MPA at 6-month intervals."	( Low-dosage esterified estrogens opposed by progestin at 6-month intervals. Ettinger, B; Pressman, A; Van Gessel, A, 2001)	0.31
" Sixty healthy women (naturally menopause for 1 to 5 years) were recruited and divided into four groups according to estrogen dosage and two kinds of progestin."	( [Observation of preventing of bone loss during early postmenopause by percutaneous estradiol in Chinese postmenopausal women]. Lin, S; Sun, A; Wei, Y, 2001)	0.31
" Further, we determined whether a reduced dosage of estrogen may maintain its beneficial effects."	( Effects of long-term and reduced-dose hormone replacement therapy on endothelial function and intima-media thickness in postmenopausal women. Akishita, M; Hashimoto, M; Hosoi, T; Kozaki, K; Miyao, M; Ouchi, Y; Toba, K; Yoshizumi, M, )	0.13
" We conclude that in healthy, postmenopausal Taiwanese women, RLX 60 mg given daily has favorable results in BMD, bone turnover and serum lipids, although the dosage we used showed a potency less than that of conventional CCEP."	( Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Cheng, WC; Hsu, SH; Huang, KE; Pan, HA; Tsai, KS; Wu, MH; Yen, BL; Yen, ML, 2001)	0.31
" In a third, non-randomized treatment period after a second wash-out interval, each woman received a combination of simvastatin and postmenopausal hormone therapy in the same dosage regimens as above."	( Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. Darling, GM; Davis, SR; Johns, JA; McCloud, PI, 1999)	0.3
" Administration of doxifluridine (5'-DFUR: Furtulon) (1,200 mg/day, 5 day continuous dosing followed by 2 day washout) and medroxyprogesterone acetate (MPA: Hysron H) (1,200 mg/day) was followed by chemotherapy consisting of intraarterial infusion of 100 mg of docetaxel (TXT: Taxotere), once monthly, via the left internal thoracic artery and left lateral thoracic artery."	( [One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful]. Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I, 2002)	0.52
" Gynecologists should consider the following criteria when selecting the ideal progestin for hormone replacement therapy: adjustment of dosage of progestin and estrogen over 3-6 months to maintain the beneficial effects of the estrogen and to minimize the adverse effects of the progestin, progestin dosage sufficient to protect against endometrial hyperplasia and cancer, economical progestin, and minimization of weight gain, depression, oral intolerance, and androgenic action."	( Progestogens in gynaecological practice. Bharucha, MR, 1995)	0.29
" The state of the art regarding long-acting contraception is reviewed with a thorough discussion of the process of development, dosage requirements, and method of delivery of the following types of contraceptives: 1) injectable depot formulations; 2) subdermal implants; 3) medical intrauterine systems; 4) medicated intravaginal systems; 5) medicated intracervical systems; and 6) biodegradable systems."	( Long-acting steroidal contraceptive systems. Beck, LR; Cowsar, DR; Pope, VZ, 1980)	0.26
" Common dosage is 150 mg every 3 months and usually is administered during the 1st week of the menstrual cycle."	( Depo Provera: still controversial. Wren, LM, 1988)	0.27
" For the development of an ideal method of reversible male contraception using sex hormones, a new combination with the lowest dosage of Depo-Provera and Depo-Testosterone should be developed by which full suppression of spermatogenesis could be attained in a limited period of time."	( Clinical trial on reversible male contraceptive with long-acting sex hormones. Kim, SI; Kwon, EH; Lee, HY, 1979)	0.26
" The risk of developing these diseases has declined as the dosage of hormones in the pill has been decreased."	( The state of the contraceptive art. Duarte, J; Tyrer, LB, 1983)	0.27
"Contraceptive use of normal dosed progestins continues to be useful for many women who cannot use other contraceptive methods, but appropriate use depends on perfect knowledge of their modes of action, advantages, disadvantages, dosages, and duration of action."	( [Contraception using normal dose progestins]. Pelissier-langbort, C, 1984)	0.27
" This dosage was raised to 200 mg and the 6-monthly dose is 400 mg."	( Large-scale MPA injections. , 1967)	0.25
" Each women received a 150 mg dosage intramuscularly of Depo-Provera."	( Depo-provera: clinical evaluation. Mukherjea, M, 1981)	0.26
"The McCormick Hospital's Family Planning program in Chiang Mai, Thailand surveyed all admissions to the hospital for carcinoma of the endometrium in light of the discovery by the Upjohn Company that 2 monkeys had developed endometrial carcinoma when given 50x the dosage of Depo-Provera."	( Endometrial carcinoma survey in Thailand. Mcdaniel, EB, 1979)	0.26
" Dosage is increased only when break through bleeding occurs."	( Newer synthetic progestins for the treatment of endometriosis. Kistner, RW, 1970)	0.25
"25/l00 woman years on the standard dosage of l50 mg per 3-monthly injection."	( Depo-Provera: just another contraceptive? Jones, M, 1978)	0.26
" DMPA as a contraceptive agent is generally given at a dosage of 150 mg every 90 days."	( Statement on injectable contraception. , 1982)	0.26
"To identify the optimal dosage of 17beta-estradiol gel + oral progestin for preventing bone loss in postmenopausal Chinese women."	( Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women. Chen, F; de Lignieres, B; Lin, S; Qin, M; Sun, A; Wei, Y; Yu, W; Zhang, Y, 2002)	0.31
" In both studies only one HRT preparation was tested, conjugated equine oestrogens (CEE) combined with medroxyprogesterone acetate (MPA), using one fixed dosage combination."	( Are pharmacological considerations of relevance in hormone replacement therapy for prevention of chronic disease? Lippert, TH; Mueck, AO; Seeger, H, 2003)	0.53
"In the absence of published data on serum medroxyprogesterone acetate (MPA) levels in South African users, this study examines such levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval."	( Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. Beksinska, M; Botha, J; McFadyen, L; Smit, J, 2004)	1.07
" Sixty healthy women (natural menopause for 1 to 5 years) were recruited and divided into four groups according to the dosage of estrogen and two kinds of progestin."	( [Monitoring the breast changes of Chinese postmenopausal women under long-term hormone replacement therapy by mammary ultrasonography]. Huang, MT; Jiang, YX; Lin, SQ; Zhang, Y; Zhou, YZ, 2004)	0.32
"The lower combined dosage is recommended for further testing in an expanded clinical trial or contraceptive efficacy study."	( [Effect of injection of testosterone undecanoate and depot medroxyprogesterone acetate on the suppression of spermatogenesis]. Bremner, WJ; Chen, Z; Gu, Y; Ma, D; Tang, W; Tong, J; Wang, X; Yuan, D, 2004)	0.57
" Serum concentrations of MPA, progesterone, estradiol, luteinizing hormone, and follicle-stimulating hormone were measured during the 91-day dosing interval and for an additional 15 days thereafter."	( Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Bode, FR; Jain, J; Rahnny, MH; Ross, D; Toh, YC, 2004)	0.57
"0] kg/m(2)) belonging to 5 ethnic groups (Chinese, Filipino, Indian, Malaysian, and Thai) were included in the study Ovulation suppression was maintained throughout the 91-day dosing interval, regardless of ethnicity or injection site."	( Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Bode, FR; Jain, J; Rahnny, MH; Ross, D; Toh, YC, 2004)	0.57
" Regardless of the dosage of progestin used, there was no impact on homocysteine metabolism after 3 years of therapy."	( Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. Hsu, SC; Lee, JN; Liu, CM; Long, CY; Tsai, EM; Yang, CH, 2005)	0.57
" PRB cDNA was effectively transfected and in the transfectant MPA at 1 x 10(-6) M, the dosage suppressing growth, induced p21 and p27expression."	( Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA. Arai, T; Hamano, M; Jobo, T; Kamata, Y; Kawaguchi, M; Kuramoto, H; Nishimura, Y; Obokata, A; Watanabe, J, 2006)	1.78
"5 dosage or after ccHRT discontinuation."	( A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. Heikkinen, J; Timonen, U; Vaheri, R, 2006)	0.33
"Serial plasma and intracellular zidovudine pharmacokinetics following oral and intravenous dosing were determined in 18 men and 20 women treated with zidovudine."	( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006)	0.33
"Men exhibited higher area under the concentration versus time curve for intracellular zidovudine and zidovudine-monophosphate following oral and intravenous dosing and higher zidovudine triphosphate following oral dosing."	( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006)	0.33
" Levels of disulfated metabolites in serum and tissues were higher (3- to 5-fold) after multiple dosing than after a single dose."	( Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. Blok, LJ; Burger, CW; Hanifi-Moghaddam, P; Kloosterboer, HJ; Verheul, HA, 2007)	0.34
" There was a dose-response association between baseline obesity, particularly as measured by waist circumference, with more than double the risk of incident symptomatic GER at 1 year among women with the largest waist circumference (>or=114 cm) compared with a normal waist circumference (70-80 cm)."	( Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Liu, S; Margolis, KL; Tinker, LF; Ye, W; Zheng, Z, 2008)	0.35
" Hormone therapy use should be limited to the treatment of menopausal symptoms at the lowest effective dosage over the shortest duration possible, and continued use should be reevaluated on a periodic basis."	( ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. , 2008)	0.35
" Results were robust across various dose-response models."	( Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Hernán, MA; Hernández-Díaz, S; Logan, R; Robins, JM; Toh, S, 2010)	0.36
" These results justify larger studies to define a more adequate dosage of OMP/PT and to confirm its efficacy and safety."	( Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Meduri, G; Soufir, JC; Ziyyat, A, 2011)	0.61
" The median dosing period was 64 months (range 28-92 months)."	( Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma. Mizuno, M; Nakanishi, T; Nawa, A; Yatabe, Y, 2012)	0.78
" Young patients with histologically confirmed Grade 1 endometrioid adenocarcinoma that is presumably confined to the endometrium, who desired to preserve their fertility potential, undergo levonorgestrel-releasing intrauterine system insertion and are administered medroxyprogesterone acetate at a dosage of 500 mg/day concurrently."	( Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009). Hong, SR; Kim, JW; Kim, MK; Lee, TS; Nam, BH; Seong, SJ; Suh, KS, 2012)	0.91
" Our study also provided new insight into the dosage of progesterone and it's derivant in the hormone replacement therapy for pregnant woman."	( Progesterone signaling/miR-200a/zeb2 axis regulates self-renewal of mouse embryonic stem cells. Ai, Y; Duan, T; Li, Y; Liu, Q, 2014)	0.4
" When Depo-Provera-treated female rhesus macaques were dosed with GSK744 LA (50 mg/kg) monthly, systemic and tissue drug concentrations were lower than previously observed in male rhesus macaques."	( A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Andrews, CD; Blanchard, J; Boente-Carrera, M; Cheng-Mayer, C; Ford, S; Gettie, A; Ho, DD; Hong, Z; Markowitz, M; Mohri, H; Rodriguez, K; Russell-Lodrigue, K; Spreen, WR; St Bernard, L; Yueh, YL, 2015)	0.42
" Plasma progesterone concentrations were measured every 2 weeks after DMPA dosing through week 12."	( Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the Aweeka, F; Cohn, SE; Cramer, Y; Klingman, KL; Livingston, E; Luque, AE; Park, JG; Watts, DH; Weinberg, A, 2015)	0.9
"Use of TDF/FTC did not appear to affect serum MPA levels, however we found lower than expected MPA concentrations at the end of the dosing interval among DMPA users in the FEM-PrEP trial, the cause of which are unknown."	( Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. Agot, K; Callahan, R; Dorflinger, L; Jenkins, D; Nanda, K; Taylor, D; Van Damme, L; Wang, M, 2016)	1.88
" Outcomes included changes in symptoms, hospitalization, suicide and modifications in medication regimens such as increase or decrease in dosage or changes in type of drug."	( Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Berry-Bibee, EN; Curtis, KM; Nanda, K; Pagano, HP; Zapata, LB, 2016)	0.43
"Our data provide evidence of a dose-response relationship between DMPA and BMD loss."	( Bone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate. Bonny, AE; Gothard, MD; Lange, HL; Manos, BE; Rogers, LK, 2017)	0.68
" Points of intervention may include pre-conception initiation of folic acid, optimization of dosing of AEDs with contraceptives, guidelines for peripartum seizure treatment, and establishment of a prospective registry for WWE and their offspring."	( Contraception, pregnancy, and peripartum experiences among women with epilepsy in Bhutan. Bui, E; Clark, SJ; Dema, U; Dorji, C; Grundy, SJ; Halani, S; Lhamo, S; Mateen, FJ; Nirola, DK; Pem, T; Tshering, L, 2017)	0.46
" However, the use of MPA may lead to stronger pituitary suppression and thus may require a higher dosage of hMG and a longer duration of ovarian stimulation than that of conventional ovarian stimulation protocol."	( New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Ai, A; Chang, HY; Gao, H; Kuang, Y; Liu, Y; Long, H; Lyu, Q; Quan, X; Yu, S; Zhu, J, 2018)	0.48
" High-dose progestins may inhibit brain tumor growth by downregulating PR-B, yet the dosage thresholds may differ between glial and meningeal tumors due to higher total PR expression in meningiomas."	( Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma. Altinoz, MA; Elmaci, I; Ozpinar, A, 2019)	0.51
" Dose-response results further suggest that effects of contraceptives containing MPA on HIV-1 acquisition and disease progression may be critically dependent on dose, time after injection and intrinsic factors that affect serum concentrations in women."	( Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels. Avenant, C; Bick, AJ; Govender, Y; Hapgood, JP; Maritz, MF; Ray, RM; Tomasicchio, M; Woodland, JG, 2018)	1.92
" Herein, we used dose-response studies to delimit DMPA doses and serum MPA levels in mice associated with impaired genital mucosal barrier function and enhanced susceptibility to low-dose herpes simplex virus type 2 (HSV-2) infection."	( Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion. Aceves, KM; Cherpes, TL; Quispe Calla, NE; Torres, A; Vicetti Miguel, RD, 2019)	0.99
" MPA clearance was higher than in women with HIV not on ART, leading to subtherapeutic concentrations of MPA in 12% of women, suggesting that more frequent dosing might be needed."	( Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Badal-Faesen, S; Cohn, SE; Coughlin, K; Cramer, Y; Dooley, K; Firnhaber, C; Godfrey, C; Kendall, MA; Mawlana, S; Mcilleron, H; Mngqibisa, R; Omoz-Oarhe, A; Roa, J; Robinson, J; Rosenkranz, SL; Samaneka, W; Schnabel, D; Wu, XS, 2020)	0.82
" The most effective dosage was 400 mg of MPA, considering both the minimal follicular growth during the IVD treatment period and the lesser numbers of persistent follicles."	( Effects of intravaginal devices containing different dosages of medroxyprogesterone acetate for the control of the estrous cycle in gilts. Bernardi, ML; Bortolozzo, FP; Gasperin, BG; Mallmann, AL; Mellagi, APG; Ulguim, RDR; Wentz, I, 2019)	0.75
"1 ng/mL), resulting in contraception failure, when depot medroxyprogesterone is dosed at 12-week intervals."	( A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021)	0.87
"Study A5338 suggested that more frequent depot MPA dosing may be appropriate for women receiving rifampicin, isoniazid, and efavirenz."	( Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP, 2022)	0.98
" Subsequently in a dose-response study, CAFs showed an average of ∼20% higher cell viability when compared to BAFs, indicative of drug resistance to MPA."	( Aberrant upregulation of CDK1 contributes to medroxyprogesterone acetate (MPA) resistance in cancer-associated fibroblasts of the endometrium. Chung, I; Godoy, A; Gunasagran, Y; Mat Adenan, NA; Omar, IS; Teo, IH, 2022)	0.98

Role	Description
progestin	A synthetic progestogen.
androgen	A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
female contraceptive drug	A chemical substance or agent with contraceptive activity in females.
synthetic oral contraceptive	An oral contraceptive which owes its effectiveness to synthetic preparation.
adjuvant	Any pharmacological or immunological agent that modifies the effect of other agents such as drugs or vaccines while having few if any direct effects when given by itself.
inhibitor	A substance that diminishes the rate of a chemical reaction.
antioxidant	A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
steroid ester
acetate ester	Any carboxylic ester where the carboxylic acid component is acetic acid.
20-oxo steroid	An oxo steroid carrying an oxo group at position 20.
3-oxo-Delta(4) steroid	A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
corticosteroid	A natural or synthetic analogue of the hormones secreted by the adrenal gland.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	17.7828	0.0032	45.4673	12,589.2998	AID2517
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	26.6321	0.0447	17.8581	100.0000	AID485341
Chain A, Cruzipain	Trypanosoma cruzi	Potency	39.8107	0.0020	14.6779	39.8107	AID1476
interleukin 8	Homo sapiens (human)	Potency	74.9780	0.0473	49.4806	74.9780	AID651758
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	2.4362	0.0251	27.9203	501.1870	AID651751
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	21.7091	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	6.8583	0.1737	34.3047	61.8120	AID1346859; AID1346924
ATAD5 protein, partial	Homo sapiens (human)	Potency	29.0810	0.0041	10.8903	31.5287	AID504466
SMAD family member 3	Homo sapiens (human)	Potency	6.8583	0.1737	34.3047	61.8120	AID1346859; AID1346924
TDP1 protein	Homo sapiens (human)	Potency	13.9427	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	19.2114	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	1.7878	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	31.6228	0.0112	12.4002	100.0000	AID1030
PINK1	Homo sapiens (human)	Potency	40.8707	2.8184	18.8959	44.6684	AID624263
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	51.0057	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	7.4632	0.0004	17.9460	75.1148	AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	3.8902	0.0123	7.9835	43.2770	AID1645841
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	7.9433	0.2818	9.7212	35.4813	AID2326
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.1585	0.0002	14.3764	60.0339	AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	34.6467	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	16.6986	0.0008	17.5051	59.3239	AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	20.8735	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	24.8464	0.3758	27.4851	61.6524	AID588526; AID588527; AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	6.4709	0.0054	28.0263	1,258.9301	AID1346982; AID1346985; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	0.9641	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743080
G	Vesicular stomatitis virus	Potency	3.0901	0.0123	8.9648	39.8107	AID1645842
Parkin	Homo sapiens (human)	Potency	40.8707	0.8199	14.8306	44.6684	AID624263
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	21.8750	0.0010	24.5048	61.6448	AID588534; AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	26.4222	0.0010	19.4141	70.9645	AID588537; AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	18.7413	0.0237	23.2282	63.5986	AID588543; AID743222
IDH1	Homo sapiens (human)	Potency	29.0929	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	6.2559	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	0.0235	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	16.7855	0.0016	28.0151	77.1139	AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	26.0953	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	17.5823	0.0578	21.1097	61.2679	AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	1.2589	0.1000	9.1916	31.6228	AID1346983
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.2214	0.0041	9.9848	25.9290	AID504444
transcriptional regulator ERG isoform 3	Homo sapiens (human)	Potency	25.1189	0.7943	21.2757	50.1187	AID624246
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	8.8216	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	38.0659	0.0006	27.2152	1,122.0200	AID651741; AID743202; AID743219
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	7.0795	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	15.0473	0.0046	11.3741	33.4983	AID624296; AID624297
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	15.8489	0.0316	10.2792	39.8107	AID884; AID885
lamin isoform A-delta10	Homo sapiens (human)	Potency	35.4813	0.8913	12.0676	28.1838	AID1487
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	2.5119	0.0158	12.3113	615.5000	AID1461
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.0488	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	3.0901	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	3.0901	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	36.1093	0.0023	19.5956	74.0614	AID651631
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.0488	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Alpha-synuclein	Homo sapiens (human)	Potency	5.6234	0.5623	9.3985	25.1189	AID652106
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	16.7855	0.0266	22.4482	66.8242	AID651802
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	10.0000	0.0096	10.5250	35.4813	AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	19.7020	1.9953	25.5327	50.1187	AID624288
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	3.0901	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	15.8489	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	3.0901	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	22.5000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	15.7000	0.1100	7.1903	10.0000	AID1473738
Estrogen receptor	Homo sapiens (human)	IC50 (µMol)	0.9240	0.0000	0.7237	32.7000	AID47053; AID68882
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.0130	0.0000	0.4953	10.0000	AID47054; AID625263; AID74088
Glucocorticoid receptor	Homo sapiens (human)	Ki	0.0124	0.0001	0.3863	7.0010	AID625263; AID74227; AID74228; AID74230; AID74231; AID74234
Progesterone receptor	Homo sapiens (human)	IC50 (µMol)	2.5081	0.0000	0.5807	10.0000	AID162108; AID162110; AID162123; AID162132
Progesterone receptor	Homo sapiens (human)	Ki	0.0005	0.0003	0.0316	0.3997	AID162288; AID162289; AID162295; AID162297; AID162298; AID162469; AID267702; AID343234
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0190	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Ki	0.0086	0.0007	0.7653	7.0010	AID625263
Mineralocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	1.1970	0.0003	0.7484	10.0000	AID126266; AID126273; AID47056
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	0.0061	0.0000	0.8753	10.0000	AID38988; AID47050
Androgen receptor	Homo sapiens (human)	Ki	0.0029	0.0002	0.4240	7.2000	AID39142; AID39143; AID39145; AID39146; AID39149
Androgen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2790	0.0010	1.9794	14.1600	AID255211; AID625228
Androgen receptor	Rattus norvegicus (Norway rat)	Ki	0.0048	0.0003	1.2185	8.9270	AID625228
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0190	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	Ki	0.0086	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0190	0.0015	0.8044	5.0740	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Ki	0.0086	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0190	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Ki	0.0086	0.0007	0.7846	7.0010	AID625263
Histamine H2 receptor	Homo sapiens (human)	IC50 (µMol)	27.9200	0.0220	2.2987	10.0000	AID625270
Histamine H2 receptor	Homo sapiens (human)	Ki	27.4530	0.0006	2.1973	10.0000	AID625270
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.1970	0.0005	1.4835	7.8000	AID47056
Aldo-keto reductase family 1 member C3	Homo sapiens (human)	IC50 (µMol)	1.4059	0.0500	2.2070	10.0000	AID1630114; AID735517
Aldo-keto reductase family 1 member C2	Homo sapiens (human)	IC50 (µMol)	4.0405	0.3700	4.0951	9.2800	AID1630032; AID735519
Aldo-keto reductase family 1 member C1	Homo sapiens (human)	IC50 (µMol)	1.8000	0.0060	3.1265	7.9000	AID735521
Estrogen receptor beta	Homo sapiens (human)	IC50 (µMol)	0.9240	0.0001	0.5294	32.7000	AID47053; AID68882
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Estrogen receptor	Homo sapiens (human)	EC50 (µMol)	0.9240	0.0000	0.5305	4.4000	AID68713
Glucocorticoid receptor	Homo sapiens (human)	EC50 (µMol)	0.0100	0.0004	0.0540	1.0000	AID73773; AID73774; AID74242
Sex hormone-binding globulin	Homo sapiens (human)	Kd	0.6310	0.0002	0.3496	4.7863	AID318680
Progesterone receptor	Homo sapiens (human)	EC50 (µMol)	0.6252	0.0001	0.4047	8.2000	AID161787; AID161789; AID161790; AID161791; AID161792; AID161793; AID161794; AID161796; AID161810; AID161815; AID208678; AID208679; AID32836; AID339656; AID343211; AID47046
Androgen receptor	Homo sapiens (human)	EC50 (µMol)	0.0061	0.0000	0.2079	4.3000	AID38801
Androgen receptor	Homo sapiens (human)	Kd	0.0010	0.0003	0.5024	6.5200	AID1885023
Androgen receptor	Mus musculus (house mouse)	EC50 (µMol)	0.0061	0.0004	0.0036	0.0061	AID38802; AID39165
Estrogen receptor beta	Homo sapiens (human)	EC50 (µMol)	0.9240	0.0000	0.4795	4.8900	AID68713
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
antral ovarian follicle growth	Estrogen receptor	Homo sapiens (human)
epithelial cell development	Estrogen receptor	Homo sapiens (human)
chromatin remodeling	Estrogen receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
signal transduction	Estrogen receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Estrogen receptor	Homo sapiens (human)
androgen metabolic process	Estrogen receptor	Homo sapiens (human)
male gonad development	Estrogen receptor	Homo sapiens (human)
negative regulation of gene expression	Estrogen receptor	Homo sapiens (human)
positive regulation of phospholipase C activity	Estrogen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
response to estradiol	Estrogen receptor	Homo sapiens (human)
regulation of toll-like receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Estrogen receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Estrogen receptor	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
response to estrogen	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
stem cell differentiation	Estrogen receptor	Homo sapiens (human)
regulation of inflammatory response	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
RNA polymerase II preinitiation complex assembly	Estrogen receptor	Homo sapiens (human)
uterus development	Estrogen receptor	Homo sapiens (human)
vagina development	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord elongation	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	Estrogen receptor	Homo sapiens (human)
regulation of branching involved in prostate gland morphogenesis	Estrogen receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Estrogen receptor	Homo sapiens (human)
mammary gland alveolus development	Estrogen receptor	Homo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongation	Estrogen receptor	Homo sapiens (human)
protein localization to chromatin	Estrogen receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of miRNA transcription	Estrogen receptor	Homo sapiens (human)
regulation of epithelial cell apoptotic process	Estrogen receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
ovulation from ovarian follicle	Progesterone receptor	Homo sapiens (human)
glandular epithelial cell maturation	Progesterone receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Progesterone receptor	Homo sapiens (human)
signal transduction	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
cell-cell signaling	Progesterone receptor	Homo sapiens (human)
positive regulation of gene expression	Progesterone receptor	Homo sapiens (human)
negative regulation of gene expression	Progesterone receptor	Homo sapiens (human)
paracrine signaling	Progesterone receptor	Homo sapiens (human)
negative regulation of phosphorylation	Progesterone receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
lung alveolus development	Progesterone receptor	Homo sapiens (human)
regulation of epithelial cell proliferation	Progesterone receptor	Homo sapiens (human)
progesterone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
maintenance of protein location in nucleus	Progesterone receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Progesterone receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Mineralocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Mineralocorticoid receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
gastric acid secretion	Histamine H2 receptor	Homo sapiens (human)
immune response	Histamine H2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H2 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H2 receptor	Homo sapiens (human)
calcium ion homeostasis	Alpha-synuclein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Alpha-synuclein	Homo sapiens (human)
microglial cell activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of receptor recycling	Alpha-synuclein	Homo sapiens (human)
positive regulation of neurotransmitter secretion	Alpha-synuclein	Homo sapiens (human)
negative regulation of protein kinase activity	Alpha-synuclein	Homo sapiens (human)
fatty acid metabolic process	Alpha-synuclein	Homo sapiens (human)
neutral lipid metabolic process	Alpha-synuclein	Homo sapiens (human)
phospholipid metabolic process	Alpha-synuclein	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial membrane organization	Alpha-synuclein	Homo sapiens (human)
adult locomotory behavior	Alpha-synuclein	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-synuclein	Homo sapiens (human)
response to iron(II) ion	Alpha-synuclein	Homo sapiens (human)
regulation of phospholipase activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
regulation of glutamate secretion	Alpha-synuclein	Homo sapiens (human)
regulation of dopamine secretion	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle exocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle priming	Alpha-synuclein	Homo sapiens (human)
regulation of transmembrane transporter activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of microtubule polymerization	Alpha-synuclein	Homo sapiens (human)
receptor internalization	Alpha-synuclein	Homo sapiens (human)
protein destabilization	Alpha-synuclein	Homo sapiens (human)
response to magnesium ion	Alpha-synuclein	Homo sapiens (human)
negative regulation of transporter activity	Alpha-synuclein	Homo sapiens (human)
response to lipopolysaccharide	Alpha-synuclein	Homo sapiens (human)
negative regulation of monooxygenase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Alpha-synuclein	Homo sapiens (human)
response to type II interferon	Alpha-synuclein	Homo sapiens (human)
cellular response to oxidative stress	Alpha-synuclein	Homo sapiens (human)
SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
positive regulation of SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
regulation of locomotion	Alpha-synuclein	Homo sapiens (human)
dopamine biosynthetic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial ATP synthesis coupled electron transport	Alpha-synuclein	Homo sapiens (human)
regulation of macrophage activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of endocytosis	Alpha-synuclein	Homo sapiens (human)
negative regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
positive regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle endocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle transport	Alpha-synuclein	Homo sapiens (human)
positive regulation of inflammatory response	Alpha-synuclein	Homo sapiens (human)
regulation of acyl-CoA biosynthetic process	Alpha-synuclein	Homo sapiens (human)
protein tetramerization	Alpha-synuclein	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Alpha-synuclein	Homo sapiens (human)
neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of serotonin uptake	Alpha-synuclein	Homo sapiens (human)
regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
negative regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
excitatory postsynaptic potential	Alpha-synuclein	Homo sapiens (human)
long-term synaptic potentiation	Alpha-synuclein	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
response to interleukin-1	Alpha-synuclein	Homo sapiens (human)
cellular response to copper ion	Alpha-synuclein	Homo sapiens (human)
cellular response to epinephrine stimulus	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber organization	Alpha-synuclein	Homo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinone	Alpha-synuclein	Homo sapiens (human)
positive regulation of glutathione peroxidase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of hydrogen peroxide catabolic process	Alpha-synuclein	Homo sapiens (human)
regulation of synaptic vesicle recycling	Alpha-synuclein	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein localization to cell periphery	Alpha-synuclein	Homo sapiens (human)
negative regulation of chaperone-mediated autophagy	Alpha-synuclein	Homo sapiens (human)
regulation of presynapse assembly	Alpha-synuclein	Homo sapiens (human)
amyloid fibril formation	Alpha-synuclein	Homo sapiens (human)
synapse organization	Alpha-synuclein	Homo sapiens (human)
chemical synaptic transmission	Alpha-synuclein	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
response to nutrient	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
steroid metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of cell population proliferation	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
male gonad development	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to starvation	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
farnesol catabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cyclooxygenase pathway	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
keratinocyte differentiation	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
progesterone metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
retinol metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
retinal metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
macromolecule metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
daunorubicin metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
doxorubicin metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
regulation of retinoic acid receptor signaling pathway	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
testosterone biosynthetic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
renal absorption	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to calcium ion	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to prostaglandin stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to corticosteroid stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to jasmonic acid stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to prostaglandin D stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
negative regulation of retinoic acid biosynthetic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
regulation of testosterone biosynthetic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of endothelial cell apoptotic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
TFIIB-class transcription factor binding	Estrogen receptor	Homo sapiens (human)
transcription coregulator binding	Estrogen receptor	Homo sapiens (human)
transcription corepressor binding	Estrogen receptor	Homo sapiens (human)
transcription coactivator binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
chromatin binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor	Homo sapiens (human)
steroid binding	Estrogen receptor	Homo sapiens (human)
protein binding	Estrogen receptor	Homo sapiens (human)
calmodulin binding	Estrogen receptor	Homo sapiens (human)
beta-catenin binding	Estrogen receptor	Homo sapiens (human)
zinc ion binding	Estrogen receptor	Homo sapiens (human)
TBP-class protein binding	Estrogen receptor	Homo sapiens (human)
enzyme binding	Estrogen receptor	Homo sapiens (human)
protein kinase binding	Estrogen receptor	Homo sapiens (human)
nitric-oxide synthase regulator activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor binding	Estrogen receptor	Homo sapiens (human)
estrogen response element binding	Estrogen receptor	Homo sapiens (human)
identical protein binding	Estrogen receptor	Homo sapiens (human)
ATPase binding	Estrogen receptor	Homo sapiens (human)
14-3-3 protein binding	Estrogen receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Estrogen receptor	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
androgen binding	Sex hormone-binding globulin	Homo sapiens (human)
protein binding	Sex hormone-binding globulin	Homo sapiens (human)
steroid binding	Sex hormone-binding globulin	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
transcription coactivator binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
DNA binding	Progesterone receptor	Homo sapiens (human)
nuclear steroid receptor activity	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor activity	Progesterone receptor	Homo sapiens (human)
steroid binding	Progesterone receptor	Homo sapiens (human)
protein binding	Progesterone receptor	Homo sapiens (human)
zinc ion binding	Progesterone receptor	Homo sapiens (human)
enzyme binding	Progesterone receptor	Homo sapiens (human)
identical protein binding	Progesterone receptor	Homo sapiens (human)
ATPase binding	Progesterone receptor	Homo sapiens (human)
estrogen response element binding	Progesterone receptor	Homo sapiens (human)
nuclear receptor activity	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Mineralocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Mineralocorticoid receptor	Homo sapiens (human)
nuclear steroid receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
steroid binding	Mineralocorticoid receptor	Homo sapiens (human)
protein binding	Mineralocorticoid receptor	Homo sapiens (human)
zinc ion binding	Mineralocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Mineralocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Mineralocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Mineralocorticoid receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
histamine receptor activity	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H2 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H2 receptor	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
retinal dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
aldo-keto reductase (NADPH) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
phenanthrene 9,10-monooxygenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin D2 11-ketoreductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
geranylgeranyl reductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
ketoreductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin-F synthase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
phenanthrene 9,10-monooxygenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
carboxylic acid binding	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
indanol dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
aldo-keto reductase (NADPH) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
protein binding	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
phenanthrene 9,10-monooxygenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
carboxylic acid binding	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
3beta-hydroxy-5beta-steroid dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
androsterone dehydrogenase (B-specific) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
indanol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor beta	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor beta	Homo sapiens (human)
DNA binding	Estrogen receptor beta	Homo sapiens (human)
nuclear steroid receptor activity	Estrogen receptor beta	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor beta	Homo sapiens (human)
steroid binding	Estrogen receptor beta	Homo sapiens (human)
protein binding	Estrogen receptor beta	Homo sapiens (human)
zinc ion binding	Estrogen receptor beta	Homo sapiens (human)
enzyme binding	Estrogen receptor beta	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor beta	Homo sapiens (human)
estrogen response element binding	Estrogen receptor beta	Homo sapiens (human)
receptor antagonist activity	Estrogen receptor beta	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nucleoplasm	Estrogen receptor	Homo sapiens (human)
transcription regulator complex	Estrogen receptor	Homo sapiens (human)
cytoplasm	Estrogen receptor	Homo sapiens (human)
Golgi apparatus	Estrogen receptor	Homo sapiens (human)
cytosol	Estrogen receptor	Homo sapiens (human)
plasma membrane	Estrogen receptor	Homo sapiens (human)
membrane	Estrogen receptor	Homo sapiens (human)
chromatin	Estrogen receptor	Homo sapiens (human)
euchromatin	Estrogen receptor	Homo sapiens (human)
protein-containing complex	Estrogen receptor	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
extracellular region	Sex hormone-binding globulin	Homo sapiens (human)
extracellular exosome	Sex hormone-binding globulin	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Progesterone receptor	Homo sapiens (human)
mitochondrial outer membrane	Progesterone receptor	Homo sapiens (human)
cytosol	Progesterone receptor	Homo sapiens (human)
chromatin	Progesterone receptor	Homo sapiens (human)
nucleus	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Mineralocorticoid receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Mineralocorticoid receptor	Homo sapiens (human)
cytosol	Mineralocorticoid receptor	Homo sapiens (human)
chromatin	Mineralocorticoid receptor	Homo sapiens (human)
receptor complex	Mineralocorticoid receptor	Homo sapiens (human)
nucleus	Mineralocorticoid receptor	Homo sapiens (human)
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
plasma membrane	Glycine receptor subunit beta	Rattus norvegicus (Norway rat)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
synapse	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
dendrite	Histamine H2 receptor	Homo sapiens (human)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
nucleus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytoplasm	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
extracellular exosome	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
cytosol	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
extracellular exosome	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Estrogen receptor beta	Homo sapiens (human)
nucleoplasm	Estrogen receptor beta	Homo sapiens (human)
mitochondrion	Estrogen receptor beta	Homo sapiens (human)
intracellular membrane-bounded organelle	Estrogen receptor beta	Homo sapiens (human)
chromatin	Estrogen receptor beta	Homo sapiens (human)
nucleus	Estrogen receptor beta	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID267702	Displacement of [3H]progesterone from Progesterone receptor	2006	Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14	Docking and three-dimensional quantitative structure-activity relationship (3D QSAR) analyses of nonsteroidal progesterone receptor ligands.
AID343210	Agonist activity at human progesterone receptor relative to progesterone	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID208678	Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line.	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
AID735517	Inhibition of recombinant AKR1C3 (unknown origin) assessed as decrease in oxidation of 1-acenaphthenol substrate by spectrophotometric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
AID162298	The binding affinity measured using baculovirus-expressed hPR-A in sf21 cells.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID1473764	Drug concentration at steady state in human at 5 to 10 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID126273	Inhibitory activity against human Mineralocorticoid receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID735521	Inhibition of human recombinant AKR1C1 expressed in Escherichia coli assessed as decrease in oxidation of 1-acenaphthenol substrate by spectrophotometric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
AID1663681	Inhibition of colony formation in progesterone sensitive human Ishikawa cells at 20 to 30 uM	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID1473763	AUC in human at 5 to 10 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID339656	Agonist activity at human progesterone receptor	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID74242	Effective concentration against GR (glucocorticoid receptor)	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
AID161975	Human progesterone receptor (hPR) antagonist efficacy was determined as a function (%) of maximal inhibition of progesterone at EC50 value.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID161979	Percent agonistic effect towards human progesterone receptor in T47D breast cancer cells	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID161968	Antagonist activity against hPR (human progesterone receptor) compared to that of progesterone (100%)	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID74228	Inhibition of Dexamethasone binding to human glucocorticoid receptor expressed in baculovirus SF-12 cells	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID68718	Agonist efficacy as percent inhibition of agonist binding to Human estrogen receptor	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID161972	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID38811	Agonistic efficacy against human androgen receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID38801	Agonistic activity against Human androgen receptor(hAR) expressed in CV-1 cells	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID1663700	Antitumor activity against human Ishikawa cells xenografted in mouse assessed as tumor growth inhibition at 30 mg/kg measured after 28 days relative to control	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID39149	Binding affinity was determined on Human androgen receptor (hAR) using progesterone as radioligand.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID179992	In vivo subcutaneous effective dose in decidualization assay in female rat	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines.
AID1150121	Relative binding affinity to human progesterone receptor	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID161787	Agonistic activity against human progesterone receptor expressed in CV-1 cells	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID300894	Effect on estrogen-induced synthesis of complement component C3 in sc dosed Sprague-Dawley rat uterus epithelial cells	2007	Bioorganic & medicinal chemistry, Oct-15, Volume: 15, Issue:20	5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.
AID1150123	Relative binding affinity to rabbit progesterone receptor	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID74231	Binding affinity against baculovirus expressed human glucocorticoid receptor (hGR)	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID161810	Effective concentration against PR (progesterone receptor)	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
AID231247	Relative potency for human glucocorticoid and progesterone receptors	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID162469	Binding affinity towards human progesterone receptor A isoform using progesterone as radioligand	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID73773	Agonist activity against Human glucocorticoid receptor(hGR) expressed in CV-1 cells	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID231245	Relative potency for human androgen and progesterone receptors	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID161790	Agonist activity was determined against hPR (human progesterone receptor) compared to that of progesterone (100%)	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID161789	Agonistic activity against human progesterone receptor in T47D breast cancer cells	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID161955	Agonistic activity towards hPR-B (human progesterone receptor) in terms of efficacy expressed as percent relative to progesterone 100%.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID161948	Agonist efficacy for human progesterone receptor (hPR) was compared to that of progesterone (100%)	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID1630032	Inhibition of recombinant AKR1C2 (unknown origin) assessed as reduction in S-tetralol catalyzed oxidation in presence of NADPH by fluorescence assay	2016	ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8	Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
AID255211	Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID161791	Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID161956	Agonist activity determined against hPR (human progesterone receptor) compared to that of progesterone (100%)	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID161971	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID73776	Agonist efficacy as percent inhibition of progesterone against human glucocorticoid receptor(hGR)	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID1630033	Selectivity ratio of IC50 for recombinant AKR1C2 (unknown origin) to IC50 for recombinant AKR1C3 (unknown origin)	2016	ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8	Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
AID1663683	Antimigratory activity against progesterone-resistant human KLE cells assessed as reduction in cell migration at 10 uM after 48 hrs by transwell assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID47056	Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID1150124	Relative binding affinity to guinea pig progesterone receptor	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID38988	Inhibition of human androgen receptor at 10e-12 to 10e-5 M	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID74227	Displacement of Dexamethasone from human glucocorticoid receptor	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID343212	Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity relative to progesterone	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID68719	Agonistic efficacy against human estrogen receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID68713	Agonistic activity against Human estrogen receptor(hER) expressed in CV-1 cells	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID161793	Antagonist activity against hPR (human progesterone receptor) compared to that of progesterone (100%)	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID161792	Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID318680	Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1663669	Antiproliferative activity against human Ishikawa cells assessed as inhibition of cell viability by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID39143	Inhibition of DHT binding to human androgen receptor expressed in baculovirus SF-12 cells	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID126141	Antagonist efficacy was determined as a function (%) of maximal inhibition of an agonist in Human mineralocorticoid receptor.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID162295	Compound was evaluated for its binding affinity against baculovirus expressed Progesterone receptor	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID73778	Agonistic efficacy against human glucocorticoid receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID162123	Inhibition of 3 nM [3H]R5020 binding to progesterone receptor in human T47D cells	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
AID162132	Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines.
AID179653	Compound was Dawley rats expressed as response to MPA at 1 mg/mouse	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
AID300875	Antagonist activity at progesterone receptor expressed in T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity	2007	Bioorganic & medicinal chemistry, Oct-15, Volume: 15, Issue:20	5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.
AID73777	Agonist efficacy as percent inhibition of agonist binding to Human glucocorticoid receptor	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID1663673	Antiproliferative activity against human AN3CA cells assessed as inhibition of cell viability by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID73774	Effective concentration against glucocorticoid receptor in human lung A549 cells	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
AID1663670	Antiproliferative activity against human KLE cells assessed as inhibition of cell viability by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID39165	Effective concentration against Androgen receptor in mouse fibroblast L929 cells	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
AID47053	IC50 determined against human estrogen receptor in CV-1 cells	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID1663682	Antimigratory activity against progesterone sensitive human Ishikawa cells assessed as inhibition of cell migration at 10 uM after 48 hrs by transwell assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID161815	Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines.
AID343227	Progestational activity in estrone-treated ovariectomized rat assessed as effect on uterine epithelial cell height	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID126130	Agonistic efficacy against human Mineralocorticoid receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID74234	Binding affinity was determined on Human glucocorticoid receptor (hAR) using progesterone as radioligand.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID162289	Binding affinity against human progesterone receptor	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID161794	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID1150122	Relative binding affinity to sheep progesterone receptor	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID161978	Percent agonistic effect towards human progesterone receptor in CV-1 cells	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID39142	Displacement of DHT from human androgen receptor	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID227718	Binding energy by using the equation deltaG obsd = -RT ln KD	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Functional group contributions to drug-receptor interactions.
AID343229	Progestational activity in estrone-treated ovariectomized rat assessed as reduction of breast alveolar bud proliferation	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID68717	Agonist efficacy as percent inhibition of progesterone against Estrogen receptor	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID161796	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID39146	Binding affinity against baculovirus expressed human androgen receptor (hAR)	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.
AID1885023	Agonist activity at human Androgen receptor	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Therapeutic Strategies to Target the Androgen Receptor.
AID1134311	Progestational activity in 9-day old pregnant bilateral ovariectomized Sprague-Dawley albino rat assessed as viable fetus at 0.055 to 0.11 mg, sc for 3 days beginning 3 hrs prior to overiectomy measured on day 12 in presence of 17beta-estradiol	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Synthesis of medroxyprogesterone bromoacetate for affinity labeling.
AID38807	Agonist efficacy as percent inhibition of agonist binding to Human androgen receptor	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID343228	Progestational activity in estrone-treated ovariectomized rat assessed as effect on vaginal epithelial thickness	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID162110	Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID1630114	Inhibition of recombinant N-terminal His-tagged AKR1C3 (unknown origin) assessed as rate of change of pyridine nucleotide absorbance in presence of NADPH	2016	ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8	Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
AID229094	Relative potency for human estrogen and progesterone receptors	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID162288	Binding affinity was determined against hPR-A (human progesterone receptor) using progesterone radioligand in competitive binding assay	1998	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID208679	Effective concentration of progesterone receptor agonist induction of alkaline phosphatase activity in human T47D breast carcinoma cells	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
AID343211	Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID177686	Effective progestational dose on oral administration in rat decidualization model	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
AID47046	Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID74088	Inhibition of human glucocorticoid receptor at 10e-12 to 10e-5 M	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID1663671	Antiproliferative activity against human Hec1A cells assessed as inhibition of cell viability by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID1473766	Ratio of drug concentration at steady state in human at 5 to 10 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID735519	Inhibition of recombinant AKR1C2 (unknown origin) assessed as decrease in oxidation of 1-acenaphthenol substrate by spectrophotometric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
AID38802	Effective concentration against Androgen receptor	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
AID162108	Inhibition of [3H]P4 to progesterone receptor (PR) of human T47D breast carcinoma cells	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
AID126139	Antagonist efficacy determined as the percentage of maximal inhibition of progesterone against mineralocorticoid receptor	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID38806	Agonist efficacy as percent inhibition of progesterone against human androgen receptor(hAR)	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID161966	Antagonist efficacy was determined as a percentage of maximal inhibition of progesterone against human progesterone receptor	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID1663672	Antiproliferative activity against human HEC1B cells assessed as inhibition of cell viability by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
AID47048	Inhibitory concentration was determined from full dose response curves ranging from 10 E -12 to 10 E -5M in CV-1 cell	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID180134	Inhibitory progestational activity on oral administration in uterine C3 model	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists.
AID126266	Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID68882	Inhibition of binding to human estrogen receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID1473765	Ratio of drug concentration at steady state in human at 5 to 10 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID177687	Effective dose on subcutaneous administration in ovariectomized female rat decidualization model	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
AID162297	The binding affinity on Human progesterone receptor (hPR-A) using progesterone as radioligand.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID343234	Binding affinity at human progesterone receptor	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID300893	Effect on uterine decidualization in sc dosed ovariectomized Sprague-Dawley rat after 7 days	2007	Bioorganic & medicinal chemistry, Oct-15, Volume: 15, Issue:20	5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.
AID47054	Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID231248	Relative potency for human mineralocorticoid and progesterone receptors	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
AID161954	Agonist efficacy was compared to that of progesterone against human progesterone receptor (hPR)	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID74230	Binding affinity against human glucocorticoid receptor expressed in SF-12 cells	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID32836	Agonistic activity measures the ability to induce alkaline phosphatase in T47D human breast cancer cell line	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Novel pyrrole-containing progesterone receptor modulators.
AID39145	Binding affinity against human androgen receptor	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID47050	Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	956 (19.90)	18.7374
1990's	1207 (25.12)	18.2507
2000's	1433 (29.82)	29.6817
2010's	984 (20.48)	24.3611
2020's	225 (4.68)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,115 (21.76%)	5.53%
Reviews	451 (8.80%)	6.00%
Case Studies	314 (6.13%)	4.05%
Observational	19 (0.37%)	0.25%
Other	3,224 (62.93%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (138)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women [NCT02122198]		17 participants (Actual)	Interventional	2014-09-08	Completed
The Impact of Different Hormone Therapy Regimens on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness [NCT05280028]		100 participants (Anticipated)	Observational	2022-02-07	Recruiting
Pharmacodynamics (Suppression of Ovulation) and Pharmacokinetics Following a Single Subcutaneous Administration of Depo Provera® CI 150 mg/mL, Depo Provera® CI 300 mg/2 mL, or During Two Cycles of Depo-subQ Provera 104® [NCT02456584]	Phase 1	42 participants (Actual)	Interventional	2015-09-30	Completed
Etonogestrel Implant or Depot Medroxyprogesterone Acetate for Medication Abortion [NCT01356927]		40 participants (Actual)	Observational	2011-05-31	Completed
The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial [NCT02103764]	Phase 3	160 participants (Anticipated)	Interventional	2013-08-31	Active, not recruiting
The Estrogen Replacement and Atherosclerosis Trial [NCT03097120]	Phase 3	309 participants (Actual)	Interventional	1995-01-31	Completed
Is Endometrial Withdrawal Bleeding Necessary Prior to Ovulation Induction With Clomiphene Citrate? A Randomized Controlled Trial and Feasibility Study [NCT03309176]	Phase 4	42 participants (Actual)	Interventional	2016-06-21	Completed
The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates: a RCT [NCT02449161]	Phase 3	60 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Missing fund to continue)
Predictors of Abnormal Uterine Bleeding in Progestin-only Contraceptives Users [NCT03398811]		390 participants (Actual)	Observational	2018-08-01	Completed
A PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF MEDROXYPROGESTERONE ACETATE IN HEALTHY FEMALE PARTICIPANTS FOLLOWING SUBCUTANEOUS INJECTION OF SAYANA PRESS IN THE UPPER A [NCT04893798]	Phase 1	68 participants (Anticipated)	Interventional	2021-09-16	Recruiting
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Pri [NCT03018249]	Early Phase 1	50 participants (Actual)	Interventional	2017-10-11	Completed
A Randomized Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women [NCT02103660]	Phase 4	131 participants (Actual)	Interventional	2014-04-08	Completed
A 12-month Open-label Randomized Controlled Trial to Evaluate Sayana® Press Suitability for at Home Subcutaneous Self-injection Procedures in Adult Women [NCT02293694]		735 participants (Actual)	Interventional	2015-09-17	Completed
Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation [NCT00563576]		71 participants (Actual)	Interventional	2007-09-30	Completed
HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC [NCT02038335]		451 participants (Actual)	Observational	2014-02-28	Completed
Investigation of the Potential for Intramuscular Depot Medroxyprogesterone Acetate as Emergency Contraception [NCT03395756]	Early Phase 1	30 participants (Actual)	Interventional	2018-08-31	Completed
A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus [NCT00064025]	Phase 2	75 participants (Actual)	Interventional	2004-04-30	Completed
Single-center, Double-masked, Placebo-controlled Parallel-group Study of Pregnancy-related Hormones Estradiol and Medroxyprogesterone, in Conjunction With Hydrocortisone and Growth Hormone to Stimulate C-peptide Secretion in Women With T1DM [NCT01265017]	Phase 1	0 participants (Actual)	Interventional	2012-07-31	Withdrawn(stopped due to Insufficient funding)
Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma [NCT03463252]	Phase 2/Phase 3	224 participants (Anticipated)	Interventional	2018-04-01	Recruiting
A Randomized Cross-Over Study to Evaluate Local Tolerability Following Subcutaneous Administration of TV-46046 [NCT03700658]	Phase 1	27 participants (Actual)	Interventional	2019-01-15	Completed
Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera [NCT03377608]		50 participants (Actual)	Observational	2017-11-17	Completed
Prospective Assessment of Acceptability and Adherence Associated With Use of the Copper Intrauterine Device (CuT380A-IUCD) Compared to Depo-medroxyprogesterone Acetate (DMPA) Among HIV Positive Women in Lilongwe, Malawi [NCT01191203]		200 participants (Actual)	Interventional	2010-07-31	Completed
Evaluation of Haematological Improvement in Patients With Low-risk MDS by Comparing VBaP With Danazol in Patients Who Have Either Received Erythropoiesis Stimulating Agents (ESA) and Lost Response, Not Responded to ESA or Are Deemed Unlikely to Respond to [NCT04997811]	Phase 2	120 participants (Anticipated)	Interventional	2021-12-21	Recruiting
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women [NCT01296152]	Phase 2	25 participants (Actual)	Interventional	2011-05-31	Completed
Randomized Clinical Trial of Self Versus Clinical Administration of Depot Medroxyprogesterone Acetate [NCT01019369]		132 participants (Actual)	Interventional	2010-03-31	Completed
Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2023 [NCT05973253]	Phase 2/Phase 3	74 participants (Actual)	Interventional	2023-04-21	Completed
Evaluation of Female Sexual Functions in Progestogen-only Contraceptive Users [NCT02579590]		444 participants (Actual)	Observational	2017-05-01	Completed
Mucosal and Systemic Responses to Contraceptives in HIV-Infected Women in Zambia [NCT00807625]	Phase 2	66 participants (Actual)	Interventional	2008-11-30	Completed
A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs) [NCT02550067]		7,830 participants (Actual)	Interventional	2015-12-14	Completed
Continuation Rates of Self-administered Subcutaneous Depot Medroxyprogesterone Acetate and Provider-administered Intramuscular Depot Medroxyprogesterone Acetate in Patients Seeking Post-abortion Contraception [NCT05505435]	Phase 4	653 participants (Anticipated)	Interventional	2022-08-01	Recruiting
Phase II Study of Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Stage I Endometrial Adenocarcinoma With Grade 2 Differentiation or Superficial Myomectomy Invasion [NCT03567655]	Phase 2	41 participants (Anticipated)	Interventional	2018-07-15	Not yet recruiting
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) [NCT02412436]	Phase 2	62 participants (Actual)	Interventional	2015-11-03	Completed
A Randomized, Dose-range Finding Study to Evaluate Pharmacokinetics of Medroxyprogesterone Acetate Following a Single Subcutaneous Administration of TV-46046 in Healthy Women of Reproductive Age [NCT04682353]	Phase 1	60 participants (Actual)	Interventional	2020-12-14	Completed
The Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate on HIV Pre-exposure Prophylaxis (PrEP) [NCT03197961]	Early Phase 1	15 participants (Actual)	Interventional	2017-11-17	Completed
Depot-medroxy Progesterone Acetate Injectable Contraceptives in Lactating Women 1st Week Versus 6 Week Postpartum Initiation [NCT06100783]		120 participants (Actual)	Interventional	2021-01-01	Completed
A Study to Evaluate the Effectiveness, Pharmacokinetics, Safety, and Acceptability of Sayana® Press When Injected Every Four Months [NCT03154125]	Phase 3	750 participants (Actual)	Interventional	2017-09-22	Completed
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer [NCT05247268]	Phase 2	104 participants (Anticipated)	Interventional	2022-03-11	Recruiting
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen [NCT00026286]	Phase 3	0 participants	Interventional	2000-11-28	Completed
A Study to Evaluate Suppression of Ovulation Following a Single Subcutaneous Administration of Various Doses of Depo-Provera CI [NCT02732418]	Phase 1	60 participants (Actual)	Interventional	2016-12-02	Completed
A Multicenter, Randomized, Open Label, Parallel Group, Active Control Study to Evaluate the Efficacy and Safety of LNG IUS (Mirena®) as Compared to Medroxyprogesterone Acetate During 6 Cycles of Treatment in Patients With Idiopathic Menorrhagia [NCT00360490]	Phase 3	165 participants (Actual)	Interventional	2006-07-31	Completed
A Phase II, Randomized, Double-blind, Active-controlled Study to Assess the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis [NCT00437658]	Phase 2	252 participants (Actual)	Interventional	2006-12-11	Completed
The Effect of Male Hormonal Contraceptive Regimens on Prostate Tissue In Normal Men [NCT00490555]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2009-01-31	Completed
Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma [NCT01011751]	Phase 3	311 participants (Actual)	Interventional	2004-04-30	Completed
Pharmacist-Administered Injections of Depo-Medroxyprogesterone Acetate for Contraception: A Pilot Randomized Controlled Trial [NCT00775047]		50 participants (Actual)	Interventional	2006-08-31	Completed
Comparing the Safety and Efficacy in the Use of Dienogest, Leuprolide Acetate, DMPA and Combined Oral Contraceptive Pills (Microgynon) on Endometriosis Patients After Conservative Surgery [NCT06145438]	Phase 3	100 participants (Anticipated)	Interventional	2023-09-04	Recruiting
Uterine Cancer Risk Reducing Strategies in Postmenopausal Women [NCT05651282]	Phase 4	250 participants (Anticipated)	Interventional	2023-03-15	Recruiting
A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients With Advanced Endometrial Carcinoma [NCT00739830]	Phase 2	130 participants (Actual)	Interventional	2008-08-31	Completed
The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder [NCT01822288]	Phase 4	125 participants (Actual)	Interventional	2012-11-16	Completed
The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia [NCT02872818]	Phase 4	40 participants (Actual)	Interventional	2014-10-31	Completed
Humatrope Treatment to Final Height in Turner's Syndrome [NCT00191113]	Phase 3	154 participants (Actual)	Interventional	1989-02-28	Completed
A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women [NCT00808132]	Phase 3	1,886 participants (Actual)	Interventional	2009-01-31	Completed
[NCT00000559]	Phase 3	0 participants	Interventional	1995-03-31	Completed
Herbal Alternatives for Menopause Symptoms: A Randomized Trial [NCT00169299]	Phase 4	351 participants	Interventional	2001-06-30	Active, not recruiting
Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause [NCT02943655]	Phase 3	240 participants (Actual)	Interventional	2017-11-01	Completed
Male Hormonal Contraception Development: Suppression of Spermatogenesis With the Addition of a Potent GnRH Antagonist (Acyline) to Testosterone and DMPA (ACY-5) -Sub-Study (HOP 5) [NCT00156650]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2004-12-31	Completed
Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspensio [NCT00543634]	Phase 1	30 participants (Anticipated)	Interventional	2007-10-31	Completed
A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehyperten [NCT00420342]	Phase 2	92 participants (Actual)	Interventional	2007-01-31	Completed
Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. [NCT01056042]	Phase 4	112 participants (Anticipated)	Interventional	2007-06-30	Completed
A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia [NCT01074892]	Phase 4	170 participants (Actual)	Interventional	2005-05-31	Completed
Co-benefits of Co-delivery of Long-acting Antiretrovirals and Contraceptives [NCT05044962]		700 participants (Anticipated)	Interventional	2021-11-26	Recruiting
Effect of Progestin-Induced Endometrial Shedding on Ovulation Induction Cycles With Clomiphene Citrate: A Randomized Study [NCT01966575]	Phase 4	0 participants (Actual)	Interventional	2013-10-31	Withdrawn(stopped due to Recent findings suggest that letrozole may be a superior Clomiphene Citrate.)
Hormonal Replacement Therapy and Small Artery Function [NCT00564031]	Phase 3	66 participants (Actual)	Interventional	2003-01-31	Completed
Pharmacokinetics of Subcutaneous Depot Medroxyprogesterone Acetate Injected in the Upper Arm [NCT01143207]		26 participants (Actual)	Interventional	2010-05-31	Completed
Hormonal Contraception and the Risk of HIV Acquisition [NCT00006324]		6,360 participants	Interventional	1999-12-31	Completed
[NCT00006133]		970 participants	Interventional	2000-06-30	Completed
[NCT00000466]	Phase 3	0 participants	Interventional	1987-09-30	Completed
Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women [NCT02272647]	Phase 1	47 participants (Actual)	Interventional	2014-12-31	Completed
A Pivotal Study to Evaluate the Bioequivalence of 150 mg/1 mL Medroxyprogesterone Acetate Injection in Postmenopausal Women [NCT00830414]	Phase 1	124 participants (Actual)	Interventional	2002-04-30	Completed
Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia [NCT03675139]	Phase 3	471 participants (Actual)	Interventional	2019-02-26	Completed
Effects of Estradiol and Soy on Menopausal Symptoms [NCT00997893]	Phase 2	96 participants (Actual)	Interventional	2009-12-31	Completed
Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study [NCT01109979]	Phase 4	24 participants (Actual)	Interventional	2009-12-31	Completed
Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users [NCT01421368]	Phase 1	72 participants (Actual)	Interventional	2012-03-31	Completed
Male Hormonal Contraceptive Development: Suppression of Spermatogenesis With the Addition of a Potent Antagonist (Acyline) to Testosterone and DMPA (ACY-5) [NCT00161447]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2004-05-31	Completed
Estrogen, HDL, and Coronary Heart Disease in Women [NCT00083824]	Phase 2/Phase 3	309 participants (Actual)	Interventional	2004-03-31	Completed
A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumurate Switched to Tenofovir Alafenamide Fumarate Based Anti-Retroviral Therapy [NCT03916328]	Phase 4	330 participants (Anticipated)	Interventional	2019-12-03	Recruiting
The Rate of Embryo Euploidy in Women Treated With Progestin-primed Ovarian Stimulation Versus Conventional Ovarian Stimulation: a Randomized Controlled Trial [NCT04654741]	Phase 4	396 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma [NCT05675787]	Phase 2	82 participants (Anticipated)	Interventional	2023-01-06	Recruiting
Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial: The Role of Progestin-induced Endometrial Shedding in PCOS (PIES in PCOS) [NCT01718444]		27 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to The primary investigator moved from academic practice to join a private group, and could not get any one to take over as PI for the study.)
[NCT02894151]	Phase 2	50 participants (Actual)	Interventional	2015-04-30	Completed
MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial [NCT00577122]	Phase 2	30 participants (Actual)	Interventional	2007-07-31	Completed
[NCT00004650]	Phase 3	150 participants	Interventional	1993-08-31	Completed
Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities [NCT01472315]	Phase 2/Phase 3	34 participants (Actual)	Interventional	2000-01-31	Completed
Effects of Tibolone Treatment on the Endometrium [NCT00294463]	Phase 4	35 participants	Interventional	2003-02-28	Completed
Hormonal Contraception, Cervical Ectopy, and STDs [NCT00091728]		1,200 participants	Observational	1997-09-30	Terminated
Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls [NCT00139685]	Phase 4	350 participants	Interventional	1998-04-30	Completed
Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome) [NCT00743574]		36 participants (Actual)	Interventional	2008-08-31	Completed
An Observational Pharmacokinetic Study to Evaluate Drug-drug Interactions Between Doravirine-containing ART and Hormonal Contraceptives Among Women Living With HIV in South Africa. [NCT04669678]	Phase 4	105 participants (Anticipated)	Interventional	2021-11-17	Recruiting
Effect of Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding Continuation, Contraceptive Continuation, and Postpartum Depression: a Randomized Trial [NCT01463202]	Phase 4	184 participants (Actual)	Interventional	2011-11-30	Completed
Treatment of Non-Gestational Acute Uterine BleedingComparing Oral Medroxyprogesterone Acetate and Monophasic Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol [NCT00350480]		240 participants	Interventional	2003-04-30	Completed
Quantification of Immune Cells in Women Using Contraception [NCT01873170]		326 participants (Actual)	Observational	2013-08-31	Completed
Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women: a Cluster-randomized Trial [NCT04005391]		208 participants (Actual)	Interventional	2018-10-23	Completed
Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Hormone Replacement Therapy [NCT00000419]	Phase 3	350 participants	Interventional	1996-04-30	Terminated
Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC [NCT00033358]	Phase 2	52 participants (Actual)	Interventional	2002-02-28	Completed
Alzheimer's Disease: Therapeutic Potential of Estrogen [NCT00066157]	Phase 2/Phase 3	42 participants (Actual)	Interventional	2001-09-30	Completed
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected W [NCT00016601]		76 participants	Interventional	2001-06-30	Completed
Endometrial Biopsy in Progestin Contraceptive Users [NCT05760144]	Early Phase 1	52 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Phase III Comparison of Depomedroxyprogesterone Acetate (DPROV) to Venlafaxine for Managing Hot Flashes [NCT00030914]	Phase 3	227 participants (Actual)	Interventional	2002-04-30	Completed
Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia [NCT00123175]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to Study has never received funding and has never been initiated)
A Phase I, Pharmacokinetic Study of Hormone Replacement Therapy in HIV-1-Infected, Postmenopausal Women on Nelfinavir, Lopinavir/Ritonavir, or Efavirenz [NCT00044837]	Phase 1	120 participants	Interventional		Terminated
Effects of Different Progesterone Containing Contraceptive Methods on Safety and Endogenous Progesterone Level [NCT05742503]		80 participants (Actual)	Observational [Patient Registry]	2021-03-30	Completed
Tranexamic Acid Versus Depot-Medroxyprogesterone Acetate in the Treatment of Perimenopausal Irregular Uterine Bleeding: Randomized Clinical Trial [NCT04710017]		110 participants (Anticipated)	Interventional	2021-02-01	Recruiting
PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [NCT00291369]	Phase 3	456 participants	Interventional	1999-12-31	Completed
Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO] [NCT00416429]	Phase 3	456 participants (Anticipated)	Interventional		Completed
Heart and Estrogen-Progestin Replacement Study (HERS) [NCT00319566]	Phase 3	2,430 participants	Interventional	1992-07-31	Completed
Study of Vasomotor Symptoms in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen [NCT00332553]	Phase 2	150 participants	Interventional	2002-02-28	Completed
Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives [NCT01750476]		7 participants (Actual)	Observational	2012-12-31	Terminated(stopped due to PI and lab have re-located study to The Ohio State University)
Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized [NCT01776203]	Phase 4	8 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to Inadequate enrollment)
Pilot Trial of Use of DMPA Injection and High Dose MPA Tablets in Outpatient [NCT01148420]	Phase 4	48 participants (Actual)	Interventional	2009-01-31	Completed
Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood [NCT02509767]	Phase 4	401 participants (Actual)	Interventional	2015-08-31	Completed
Relationship Between Drug Exposure and DNA Markers With Depot Medroxyprogesterone Acetate-associated Side Effects in Adolescents [NCT01461824]	Phase 3	34 participants (Actual)	Interventional	2011-09-30	Completed
Contraceptives and Dolutegravir-based ART [NCT04910711]	Phase 4	140 participants (Anticipated)	Interventional	2021-10-21	Active, not recruiting
Comparison of Cetrorelix, Medroxyprogesterone Acetate and Dydrogesterone for Preventing Premature Ovulation in Ovarian Stimulation Cycles [NCT05767086]		297 participants (Anticipated)	Interventional	2023-03-15	Recruiting
The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy [NCT02335203]	Phase 2	76 participants (Actual)	Interventional	2015-02-28	Active, not recruiting
Effect of Raloxifene on Ovulation in Women With Polycystic Ovarian Syndrome. [NCT01607320]		3 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to Over budget, slow recruitment, and personnel change)
A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III [NCT00002920]	Phase 3	313 participants (Actual)	Interventional	1997-03-31	Completed
The Therapeutic Effect of Medroxyprogesterone Acetate vs. LNG-IUS in Early-stage Endometrioid Carcinoma [NCT05565573]	Phase 2/Phase 3	148 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women [NCT00828542]		40 participants (Actual)	Interventional	2007-07-31	Completed
Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda [NCT01578447]		356 participants (Actual)	Interventional	2012-04-30	Completed
Management of Uterine Arteriovenous Malformation- a Comparison of 2 Management Possibilities- Observation vs. Progesterone Treatment/ a Randomized Control Trial [NCT05491343]	Phase 4	28 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
Tubal Patency During the Menstrual Cycle and During Treatment With Hormonal Contraceptives: a Pilot Study in Women [NCT02146248]		11 participants (Actual)	Interventional	2014-05-31	Completed
[NCT00000605]	Phase 3	0 participants	Interventional	1996-08-31	Completed
Effect of Transdermal Estradiol Replacement Therapy on Ovulation Rate in Women With Premature Ovarian Failure: A Randomized, Placebo-Controlled Trial [NCT00370019]	Phase 2	0 participants (Actual)	Interventional	2006-08-25	Withdrawn
Initiation of Injectable Contraception Immediately Postpartum Among Breastfeeding Women [NCT03844633]	Phase 4	49 participants (Actual)	Interventional	2019-03-21	Terminated(stopped due to Because of insufficient enrollment, we closed the RCT and replaced it with an observational design)
Rates of Contraceptive Failure When Unprotected Intercourse Has Occurred 6-14 Days Prior to Contraceptive Initiation [NCT02076217]		1,030 participants (Anticipated)	Observational	2014-02-28	Active, not recruiting
Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone [NCT05726903]	Phase 4	40 participants (Anticipated)	Interventional	2022-12-06	Recruiting
An Observational, Prospective, Multicentre Study to Assess the Sensitivity to Change of the SAMANTA Questionnaire in Women With Heavy Menstrual Bleeding (HMB) [NCT03751800]		422 participants (Actual)	Observational	2018-12-12	Completed
The Effect of Endometrial Shedding With Medroxyprogesterone Acetate Prior to Ovulation Induction With Clomiphene Citrate in Oligo-ovulatory and Anovulatory Women: a Pilot Study [NCT02340013]	Phase 4	50 participants (Actual)	Interventional	2013-07-31	Completed
The Impact of Contraception on Postpartum Weight Loss: a Prospective Study [NCT02144259]		100 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma [NCT02228681]	Phase 2	74 participants (Actual)	Interventional	2015-02-28	Active, not recruiting
A Randomized Control Trial to Compare the Live Birth Rate Between the Progestin-primed Ovarian Stimulation Protocol and the GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response Undergoing IVF [NCT04414761]	Phase 3	784 participants (Actual)	Interventional	2020-06-04	Completed
A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera [NCT00003179]	Phase 2	360 participants (Anticipated)	Interventional	1998-11-30	Terminated
[NCT01791413]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2012-03-31	Completed
A Prospective Cohort Study Evaluating the Impact of Three Progestin-based Hormonal Contraceptive (HC) Methods on Immunologic Changes in the Female Genital Tract (FGT) and Systemically [NCT03660046]		225 participants (Anticipated)	Observational	2018-12-07	Recruiting
Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. [NCT03300960]	Phase 3	318 participants (Actual)	Interventional	2017-10-20	Completed
Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk [NCT02357368]	Phase 4	59 participants (Actual)	Interventional	2015-02-28	Completed
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial [NCT05255653]	Phase 2/Phase 3	1,615 participants (Anticipated)	Interventional	2021-11-11	Recruiting
Metabolic Profile of Users of Hormonal and Non-hormonal Contraceptives, 5-year Follow-up [NCT03383185]		489 participants (Actual)	Observational	2010-01-01	Completed
The UMPALA Study: A Clinical Study to Assess the Impact of Contraceptives on the Cervico-Vaginal Mucosa [NCT04814927]	Phase 4	112 participants (Actual)	Interventional	2021-03-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00064025 (3) [back to overview]	Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative
NCT00064025 (3) [back to overview]	Change From Pre- to Post-treatment in Progestrogren Receptor (PR) Expression
NCT00064025 (3) [back to overview]	Change From Pre- to Post-treatment in Estrogren Receptor (ER) Expression
NCT00191113 (18) [back to overview]	Height (Centimeters [cm])
NCT00191113 (18) [back to overview]	Glycosylated Hemoglobin, Change From Baseline
NCT00191113 (18) [back to overview]	Fasting Glucose, Change From Baseline
NCT00191113 (18) [back to overview]	Maximum Fasting Insulin Values
NCT00191113 (18) [back to overview]	Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height
NCT00191113 (18) [back to overview]	Number of Participants With Any Abnormal Fasting Glucose Value
NCT00191113 (18) [back to overview]	Number of Participants With Any Abnormal Fasting Insulin Value
NCT00191113 (18) [back to overview]	Number of Participants With Hearing Loss, Audiologist Assessment
NCT00191113 (18) [back to overview]	Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value
NCT00191113 (18) [back to overview]	Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population
NCT00191113 (18) [back to overview]	Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value
NCT00191113 (18) [back to overview]	Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population
NCT00191113 (18) [back to overview]	Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment
NCT00191113 (18) [back to overview]	Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment
NCT00191113 (18) [back to overview]	Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment
NCT00191113 (18) [back to overview]	Minimum Fasting Glucose/Insulin Ratio Values
NCT00191113 (18) [back to overview]	Maximum Glycosylated Hemoglobin
NCT00191113 (18) [back to overview]	Maximum Fasting Glucose Value
NCT00360490 (15) [back to overview]	Total Number of Spotting Days
NCT00360490 (15) [back to overview]	Percentage of Patients With Successful Treatment
NCT00360490 (15) [back to overview]	Total Number of Spotting and Bleeding Days
NCT00360490 (15) [back to overview]	Total Number of Bleeding Days
NCT00360490 (15) [back to overview]	Percentage of Patients With Improvement in the Patients Overall Assessment Scale
NCT00360490 (15) [back to overview]	Percentage of Patients With Improvement in the Investigator Global Assessment Scale
NCT00360490 (15) [back to overview]	Percent Change From Baseline MBL to Mid-study MBL (Cycle 3)
NCT00360490 (15) [back to overview]	Percent Change in Serum Ferritin
NCT00360490 (15) [back to overview]	Percent Change From Baseline MBL to End of Study MBL (Cycle 6)
NCT00360490 (15) [back to overview]	Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)
NCT00360490 (15) [back to overview]	Percent Change in Hemoglobin
NCT00360490 (15) [back to overview]	Percent Change in Hematocrit
NCT00360490 (15) [back to overview]	Total Number of Bleeding Episodes
NCT00360490 (15) [back to overview]	Percentage of Subjects Who Completed the Study in Levonorgestrel Intrauterine System (LNG IUS) Group
NCT00360490 (15) [back to overview]	The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough
NCT00420342 (12) [back to overview]	Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Emotional Well-being Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Intercourse Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Medical Profession Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Relationship With Children Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Self Image Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Social Support Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Treatment Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Work Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in Endometriosis Health Profile-5 (EHP-5) Pain Dimension
NCT00437658 (29) [back to overview]	Change From Baseline in in Monthly Mean Visual Analog Scale (VAS) for Pelvic Pain
NCT00437658 (29) [back to overview]	Change From Baseline in N-telopeptide at Weeks 12, 24 and 48
NCT00437658 (29) [back to overview]	Change From Baseline in Non-menstrual Pelvic Pain Component of the CPSSS During the Treatment Period
NCT00437658 (29) [back to overview]	Change From Baseline in Pelvic Induration Component of the CPSSS During the Treatment Period
NCT00437658 (29) [back to overview]	Change From Baseline in Pelvic Tenderness Component of the CPSSS During the Treatment Period
NCT00437658 (29) [back to overview]	Change From Baseline in Total CPSSS During the Treatment Period
NCT00437658 (29) [back to overview]	Change From Baseline in in Monthly Peak Visual Analog Scale (VAS) for Pelvic Pain
NCT00437658 (29) [back to overview]	Percentage of Participants With a Response in the Dysmenorrhea Component of the CPSSS Over Time
NCT00437658 (29) [back to overview]	Percentage of Participants Using Analgesics During the Treatment Phase
NCT00437658 (29) [back to overview]	Percent Change From Baseline in Bone Mineral Density of the Spine at Weeks 12 and 48
NCT00437658 (29) [back to overview]	Percent Change From Baseline in Bone Mineral Density of the Femur at Weeks 12 and 48
NCT00437658 (29) [back to overview]	Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS Over Time
NCT00437658 (29) [back to overview]	Change From Baseline in Total CPSSS Excluding Dyspareunia During the Treatment Period
NCT00437658 (29) [back to overview]	Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24
NCT00437658 (29) [back to overview]	Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24
NCT00437658 (29) [back to overview]	Percentage of Participants With a Response in the Dysmenorrhea Component of the Composite Pelvic Signs and Symptoms Score (CPSSS) at Week 24
NCT00437658 (29) [back to overview]	Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS at Week 24
NCT00437658 (29) [back to overview]	Change From Baseline in Dysmenorrhea Component of the CPSSS During the Treatment Period
NCT00437658 (29) [back to overview]	Change From Baseline in Dyspareunia Component of the CPSSS During the Treatment Period
NCT00437658 (29) [back to overview]	Change From Baseline in EHP-5 Control and Powerlessness Dimension
NCT00490555 (5) [back to overview]	Androstenedione (AED)
NCT00490555 (5) [back to overview]	Dehydroepiandrosterone (DHEA)
NCT00490555 (5) [back to overview]	Dihydrotestosterone (DHT) Concentration
NCT00490555 (5) [back to overview]	Prostate-specific Antigen (PSA)
NCT00490555 (5) [back to overview]	Testosterone Concentration
NCT00563576 (4) [back to overview]	Number of Subjects Who Receive a 2nd Injection of Depo-Provera
NCT00563576 (4) [back to overview]	Mean Number of Bleeding or Spotting Days
NCT00563576 (4) [back to overview]	Percentage of Users Who Were Satisfied With Femring
NCT00563576 (4) [back to overview]	Percentage of Subjects Who Receive a 3rd Injection
NCT00577122 (4) [back to overview]	Clinical Benefit Rate (CR + PR + SD > 6 Months).
NCT00577122 (4) [back to overview]	MPA Trough Level > 50 ng/mL When Have Clinical Benefit
NCT00577122 (4) [back to overview]	Grade 3 or 4 Adverse Events Related to Treatment
NCT00577122 (4) [back to overview]	MPA Trough Concentration
NCT00743574 (6) [back to overview]	Fasting Insulin Levels at Study Completion After 3 Month Treatment
NCT00743574 (6) [back to overview]	AUC (Area Under a Curve at 0, 0.5, 1, 1.5 and 2 Hours) Insulin During 2 Hour GTT at Completion, at 3 Months
NCT00743574 (6) [back to overview]	AUC (Area Under the Curve at 0, 0.5, 1, 1.5 and 2 Hours) During Oral GTT at Completion, at 3 Months
NCT00743574 (6) [back to overview]	Fasting Glucose Levels at Completion of Treatment, at 3 Months
NCT00743574 (6) [back to overview]	Serum HbA1C at 3 Months
NCT00743574 (6) [back to overview]	Serum Levels of C-reactive Protein at Completion of 3 Months Treatment
NCT00808132 (13) [back to overview]	Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study
NCT00808132 (13) [back to overview]	Percentage of Participants With Uterine Bleeding
NCT00808132 (13) [back to overview]	Percentage of Participants With Cumulative Amenorrhea: Main Study
NCT00808132 (13) [back to overview]	Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Month 3: Sleep Sub-Study
NCT00808132 (13) [back to overview]	Change From Baseline in Menopause-Specific Quality of Life (MENQOL) Score at Month 3: Sleep Sub-Study
NCT00808132 (13) [back to overview]	Medical Outcomes Study (MOS) Sleep Scale at Baseline: Sleep Sub-Study
NCT00808132 (13) [back to overview]	Menopause-Specific Quality of Life (MENQOL) Score at Baseline: Sleep Sub-Study
NCT00808132 (13) [back to overview]	Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-Study
NCT00808132 (13) [back to overview]	Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 6: Osteoporosis Sub-Study
NCT00808132 (13) [back to overview]	Percent Change From Baseline in Breast Density at Month 12: Breast Density Sub-Study
NCT00808132 (13) [back to overview]	Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 6, 12: Osteoporosis Sub-Study
NCT00808132 (13) [back to overview]	Percent Change From Baseline in Bone Turnover Markers (BTMs) at Month 6 and Month 12: Osteoporosis Sub-Study
NCT00808132 (13) [back to overview]	Percentage of Participants With Breast Tenderness
NCT00828542 (1) [back to overview]	Etonogestrel-releasing Contraceptive Subdermal Implant Inserted During the Immediate Puerperium Effects on the Hemostatic System of Healthy Women Over a Period of Twelve Weeks
NCT00997893 (5) [back to overview]	Change in STAI-6 Score
NCT00997893 (5) [back to overview]	Changes in STAI-6 Scores Before and After Psychosocial Stressor Over Time
NCT00997893 (5) [back to overview]	Change in Verbal Memory, Immediate Recall
NCT00997893 (5) [back to overview]	Change in Verbal Memory, Delayed Recall
NCT00997893 (5) [back to overview]	Memory for Emotionally Valent Words and Neutral Words
NCT01019369 (2) [back to overview]	Number of Participants Continuing DMPA
NCT01019369 (2) [back to overview]	Number of Participants Continuing DMPA at 6 Months
NCT01109979 (1) [back to overview]	Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD)
NCT01143207 (6) [back to overview]	AUC 0-91 (Area Under Curve)
NCT01143207 (6) [back to overview]	MPA Concentration at Day 104 (C104)
NCT01143207 (6) [back to overview]	MPA Concentration at Day 120 (C120)
NCT01143207 (6) [back to overview]	MPA Concentration at Day 91 (C91)
NCT01143207 (6) [back to overview]	Tmax (Time to Cmax)
NCT01143207 (6) [back to overview]	Cmax (Maximal Serum Concentration of Medroxyprogesterone Acetate (MPA))
NCT01148420 (3) [back to overview]	Cessation of Bleeding Within 5 Days
NCT01148420 (3) [back to overview]	Patient Perception of the Acceptability of the Treatment
NCT01148420 (3) [back to overview]	Satisfaction and Willingness to Recommend Treatment
NCT01296152 (24) [back to overview]	RTV PK Parameter Cmax.
NCT01296152 (24) [back to overview]	RTV PK Parameter T1/2.
NCT01296152 (24) [back to overview]	RTV PK Parameter Tmax.
NCT01296152 (24) [back to overview]	RTV PK Parameter Cmin.
NCT01296152 (24) [back to overview]	Medroxyprogesterone Acetate (MPA) Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-12weeks)
NCT01296152 (24) [back to overview]	MPA PK Parameter Clearance (CL/F) Determined Based on MPA Levels.
NCT01296152 (24) [back to overview]	MPA PK Parameter Half-Life (T1/2) Determined Based on MPA Levels.
NCT01296152 (24) [back to overview]	MPA PK Parameter Maximum Plasma Concentration (Cmax) Determined Based on MPA Levels.
NCT01296152 (24) [back to overview]	MPA PK Parameter Minimum Plasma Concentration (Cmin) Determined Based on MPA Levels.
NCT01296152 (24) [back to overview]	MPA PK Parameter Time to Cmax (Tmax) Determined Based on MPA Levels.
NCT01296152 (24) [back to overview]	Percentage of Participants With Menstrual Irregularities of Grade 1 and Higher Deemed Possibly, Probably or Definitely Related to Study Treatment.
NCT01296152 (24) [back to overview]	AUC0-12hour for LPV at Baseline (Day 0) Before DMPA Administration and at Week 4 (Four Weeks After DMPA Administration)
NCT01296152 (24) [back to overview]	Cell Mediated Immunity (CMI) to HIV and the Common Opportunistic Agent Varicella-zoster Virus (VZV) Using the Enzyme-linked Immunospot (ELISPOT) Assay.
NCT01296152 (24) [back to overview]	CMI to HIV and the Common Opportunistic Agent VZV Using the Lymphocyte Proliferation Assay (LPA).
NCT01296152 (24) [back to overview]	LPV PK Parameter CL/F.
NCT01296152 (24) [back to overview]	LPV PK Parameter Cmax.
NCT01296152 (24) [back to overview]	LPV PK Parameter Cmin.
NCT01296152 (24) [back to overview]	LPV PK Parameter T1/2.
NCT01296152 (24) [back to overview]	LPV PK Parameter Tmax.
NCT01296152 (24) [back to overview]	Percentage of Participants With HIV-1 RNA Levels <400 Copies/mL.
NCT01296152 (24) [back to overview]	Percentage of Participants With Progesterone Levels Less Than the Lower Limit of Quantification (LLQ).
NCT01296152 (24) [back to overview]	Regulatory T Cells (Tregs) at Baseline, Week 4 and Week 12 Using Flow Cytometry in Freshly Thawed PBMCs.
NCT01296152 (24) [back to overview]	Ritonavir (RTV) PK Parameter AUC0-12h.
NCT01296152 (24) [back to overview]	RTV PK Parameter CL/F.
NCT01461824 (3) [back to overview]	Proportion of Participants With >5% Weight Gain at 24 Weeks
NCT01461824 (3) [back to overview]	Percent Change in Total Hip BMD From Baseline to 48 Weeks
NCT01461824 (3) [back to overview]	Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to 48 Weeks
NCT01463202 (3) [back to overview]	Rates of Postpartum Depression After Postpartum or Delayed Initiation of DMPA
NCT01463202 (3) [back to overview]	Exclusivity of Breastfeeding Among Women Who Plan to Breastfeed Their Infants After Postpartum or Delayed (4-6 Weeks Postpartum) Initiation of DMPA
NCT01463202 (3) [back to overview]	Duration of Breastfeeding Among Women Who Plan to Breastfeed Their Infants After Postpartum or Delayed (4-6 Weeks Postpartum) Initiation of DMPA
NCT01791413 (1) [back to overview]	Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Digits Span Forward and Backward, 6 Months
NCT02122198 (16) [back to overview]	Changes in Artery Compliance at 9 Months
NCT02122198 (16) [back to overview]	Changes in Artery Compliance at 6 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Controlled Oral Word Association Test, 9 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Controlled Oral Word Association Test, 6 Months
NCT02122198 (16) [back to overview]	Changes in Prefrontal Cortex Brain Activation at 9 Months
NCT02122198 (16) [back to overview]	Changes in Prefrontal Cortex Brain Activation at 6 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Digits, 9 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Trails B, 9 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Trails B, 6 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Trails A, 9 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Trails A, 6 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Stroop, 9 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: Stroop, 6 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: RAVLT, 9 Months
NCT02122198 (16) [back to overview]	Changes in Executive Cognitive Function: RAVLT, 6 Months
NCT02144259 (3) [back to overview]	Contraceptive Satisfaction
NCT02144259 (3) [back to overview]	Pregnancy Rate
NCT02144259 (3) [back to overview]	Weight
NCT02228681 (4) [back to overview]	Median Progression-free Survival
NCT02228681 (4) [back to overview]	Frequency of Response
NCT02228681 (4) [back to overview]	Median Survival
NCT02228681 (4) [back to overview]	Frequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4
NCT02357368 (4) [back to overview]	Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]	Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]	Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]	Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood
NCT02412436 (11) [back to overview]	DMPA CL/F
NCT02412436 (11) [back to overview]	Cumulative Percentage of Participants With DMPA < 0.1 ng/mL
NCT02412436 (11) [back to overview]	Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Weeks 2, 4, 6, 8, and 10
NCT02412436 (11) [back to overview]	Time at Which Participant-specific Estimated Elimination Slopes for DMPA Level Cross the Threshold of 0.1 ng/mL
NCT02412436 (11) [back to overview]	Percent of Participants Who Experienced a Grade 3 or Higher Sign/Symptom or Laboratory Abnormality
NCT02412436 (11) [back to overview]	Percent of Participants With Progesterone Levels Above 1 ng/mL at Week 12
NCT02412436 (11) [back to overview]	Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Week 12
NCT02412436 (11) [back to overview]	DMPA AUC
NCT02412436 (11) [back to overview]	DMPA Half-life
NCT02412436 (11) [back to overview]	DMPA Cmin
NCT02412436 (11) [back to overview]	DMPA Cmax
NCT02509767 (3) [back to overview]	Number of Participants Who Were Satisfied With Depot Medroxyprogesterone Acetate (DMPA sc) at One Year by Self-Report in Both the Self- and Clinic Administration Arms
NCT02509767 (3) [back to overview]	Number of Participants Who Were Satisfied With Home Use of Depot Medroxyprogesterone Acetate (DMPA sc) at One Year by Self-Report in the Self-Administration Arm
NCT02509767 (3) [back to overview]	Number of Participants With Depot Medroxyprogesterone Acetate (DMPA sc) Continuation at One Year by Self-report in Both the Self- and Clinic Administration Arms
NCT03018249 (4) [back to overview]	Percentage of Participants With a Histologic Response
NCT03018249 (4) [back to overview]	The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE)
NCT03018249 (4) [back to overview]	Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score)
NCT03018249 (4) [back to overview]	Percent of Participants With a Ki67 Response
NCT03700658 (4) [back to overview]	Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain)
NCT03700658 (4) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT03700658 (4) [back to overview]	Injection Site Pain Score, as Assessed by Numerical Rating Scale (NRS)
NCT03700658 (4) [back to overview]	Participant's Perception of Pain, as Assessed by an Overall Ranking of the 4 Study Injections From Least to Most Painful
NCT04005391 (5) [back to overview]	Number of Participants With Contraceptive Continuation at Twelve Months
NCT04005391 (5) [back to overview]	Number of Participants With Implant Use at Three Months
NCT04005391 (5) [back to overview]	Number of Participants With Repeat Pregnancy at Twelve Months
NCT04005391 (5) [back to overview]	Contraceptive Satisfaction at Twelve Months
NCT04005391 (5) [back to overview]	Number of Participants With Any Contraceptive Use at Three Months

Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative

"To determine the presence of a histologic response, the slide from the initial sample was compared to the slide from the matching hysterectomy specimen. A complete histologic response was defined as the absence of identifiable adenocarcinoma in the hysterectomy specimen section. A partial histologic response was subjectively defined in advance of the study based on criteria slightly modified from Wheeler et al. (Am J Surg Pathol 2007;31:988-98) as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample. A complete or partial histologic response was considered a histologic response in the analysis of data.~PR Positivity is based on aggregate score >0.2 (vs. <=0.2). Aggregate score based on product of staining intensity and area." (NCT00064025)
Timeframe: During the hysterectomy, which is 21-24 days after administration of depo-provera

Intervention	percentage of participants (Number)
PR Negative (<=0.2)	62.5
PR Positive (>0.2)	68.9

Intervention	centimeters (cm) (Least Squares Mean)
As-Treated No Growth Hormone	141.63
As-Treated Growth Humatrope	148.52

Intervention	percent (%) (Least Squares Mean)
Treated-As-Randomized Control	0.215
Treated-As-Randomized Humatrope	0.208

Intervention	mg / dL (Least Squares Mean)
Treated-As-Randomized Control	5.495
Treated-As-Randomized Humatrope	3.003

Intervention	Standard Deviation Score (SDS) [NCHS] (Least Squares Mean)
As-Treated No Growth Hormone	-3.30
As-Treated Growth Hormone	-2.25

Intervention	participants (Number)
	Conductive Hearing Loss	Sensorineural Hearing Loss	Mixed Hearing Loss	Unspecified Hearing Loss
As-Treated Growth Hormone	7	15	9	1
As-Treated No Growth Hormone	1	8	2	1

Intervention	Standard Deviation Score (SDS) [NCHS] (Least Squares Mean)
As-Treated No Growth Hormone	-0.09
As-Treated Growth Humatrope	0.99

Intervention	milligrams per 10^-4 Units (mg/[10^-4]U) (Mean)
As-Treated No Growth Hormone	12.5
As-Treated Growth Hormone	12.2

Intervention	milligrams per deciliter (mg/dL) (Mean)
As-Treated No Growth Hormone	85.2
As-Treated Growth Hormone	85.2

Intervention	days (Mean)
	Baseline	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	1.23	9.47	9.58	7.27	5.65	6.48	5.38
Medroxyprogesterone Acetate (MPA)	1.84	1.48	2.31	2.27	1.84	2.00	2.23

Intervention	Percentage of participants (Number)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	84.8
Medroxyprogesterone Acetate (MPA)	22.2

Intervention	Percent change (Mean)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	-61.71
Medroxyprogesterone Acetate (MPA)	-11.11

Intervention	percent change (Median)
	Baseline to cycle 3	Cycle 3 to cycle 6	Baseline to cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	13.8	48.3	68.8
Medroxyprogesterone Acetate (MPA)	0.0	16.7	14.3

Intervention	Percent change (Mean)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	-70.75
Medroxyprogesterone Acetate (MPA)	-21.54

Intervention	milliliter (mL) (Median)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	-115.13
Medroxyprogesterone Acetate (MPA)	-3.15

Intervention	percentage of participants (Number)
	0 days	30 days	60 days	90 days	120 days	150 days	180 days
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	97.53	95.06	93.83	92.59	91.36	90.12	90.12

Intervention	milliliter (mL) (Median)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours	-128.78
Medroxyprogesterone Acetate (MPA)	-17.7

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.9
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.9
1.5 mg MPA / 0.3 mg CEE (Prempro)	1.4

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.03
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-0.27
1.5 mg MPA / 0.3 mg CEE (Prempro)	2.18

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.08
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	0.06
1.5 mg MPA / 0.3 mg CEE (Prempro)	2.82

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.19
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-0.91
1.5 mg MPA / 0.3 mg CEE (Prempro)	0.57

medroxyprogesterone acetate

Cross-References

Synonyms (224)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (8)

Drug Classes (5)

Protein Targets (95)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (432)

Molecular Functions (159)

Ceullar Components (68)

Bioassays (219)

Research

Studies (4,805)

Market Indicators

Research Demand Index: 107.62

Study Types

Clinical Trials (138)

Trial Overview

Trial Outcomes

Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative

Change From Pre- to Post-treatment in Progestrogren Receptor (PR) Expression

Change From Pre- to Post-treatment in Estrogren Receptor (ER) Expression

Height (Centimeters [cm])

Glycosylated Hemoglobin, Change From Baseline

Fasting Glucose, Change From Baseline

Maximum Fasting Insulin Values

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height

Number of Participants With Any Abnormal Fasting Glucose Value

Number of Participants With Any Abnormal Fasting Insulin Value

Number of Participants With Hearing Loss, Audiologist Assessment

Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population

Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population

Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment

Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment

Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment

Minimum Fasting Glucose/Insulin Ratio Values

Maximum Glycosylated Hemoglobin

Maximum Fasting Glucose Value

Total Number of Spotting Days

Percentage of Patients With Successful Treatment

Total Number of Spotting and Bleeding Days

Total Number of Bleeding Days

Percentage of Patients With Improvement in the Patients Overall Assessment Scale

Percentage of Patients With Improvement in the Investigator Global Assessment Scale

Percent Change From Baseline MBL to Mid-study MBL (Cycle 3)

Percent Change in Serum Ferritin

Percent Change From Baseline MBL to End of Study MBL (Cycle 6)

Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)

Percent Change in Hemoglobin

Percent Change in Hematocrit

Total Number of Bleeding Episodes

Percentage of Subjects Who Completed the Study in Levonorgestrel Intrauterine System (LNG IUS) Group

The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)

Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population

Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population

Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)

Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements

Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements

Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough

Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8

Change From Baseline in EHP-5 Emotional Well-being Dimension

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-2.4
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-2.2
1.5 mg MPA / 0.3 mg CEE (Prempro)	2.0

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-2.6
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-3.7
1.5 mg MPA / 0.3 mg CEE (Prempro)	1.1

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-3.4
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-4.4
1.5 mg MPA / 0.3 mg CEE (Prempro)	1.1

Intervention	mmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-5.2
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-4.0
1.5 mg MPA / 0.3 mg CEE (Prempro)	1.0

Intervention	mmHg (Median)
	mean daytime	mean nighttime	mean trough
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.95	0.20	-1.04
1.5 mg MPA / 0.3 mg CEE (Prempro)	0.17	1.75	-0.30
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-1.56	0.67	-1.13

Intervention	mmHg (Mean)
	Systolic Blood Pressure (SBP)	Diastolic Blood Pressure (DBP)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-5.25	-1.34
1.5 mg MPA / 0.3 mg CEE (Prempro)	-4.20	0.33
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	-6.02	-0.36

Intervention	participants (Number)
	Baseline	Week 8
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	4	1
1.5 mg MPA / 0.3 mg CEE (Prempro)	4	2
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)	3	2

Intervention	units on a scale (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24
DMPA-SC	-5.1	-13.4	-14.6	-14.9	-18.4	-25.5
Elagolix 150 mg QD	-12.7	-20.6	-18.0	-21.1	-20.8	-24.1
Elagolix 75 mg BID	-10.4	-16.0	-21.9	-20.7	-22.8	-23.8

Intervention	nM bone collagen equivalents (BCE) (Least Squares Mean)
	Week 12	Week 24	Week 48
DMPA-SC	0.74	-0.24	-1.39
Elagolix 150 mg QD	0.94	0.23	-1.28
Elagolix 75 mg BID	0.57	-0.30	-1.53

Intervention	percentage of participants (Number)
	Antiinflammatory/Antirheumatics, Non-Steroids	Opioids	Other Analgesics and Antipyretics
DMPA-SC	68.7	33.7	34.9
Elagolix 150 mg QD	65.5	23.8	45.2
Elagolix 75 mg BID	64.3	25.0	46.4